腫瘍病理鑑別診断アトラス　肝癌　第2版

出版社： 文光堂
著者：
発行日： 2020-11-06
分野： 臨床医学：基礎  >  臨床病理学
ISBN： 9784830622540
シリーズ： 腫瘍病理鑑別診断アトラス
電子書籍版： 2020-11-06 （第2版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

19,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

19,800 円(税込)

購入する

商品紹介

腫瘍病理鑑別診断シリーズ「肝癌」，待望の第2版．2010年の初版発行から約10年，2019年にはWHO分類第5版が発行されるなど，日々そのコンセンサスやトピックが更新されてきた．そうした状況を踏まえて，今回，肝臓病理のエキスパートが精選した病理写真とともに，定義や概念，診断上の要点を解説．肝癌病理診断の標準化を図りつつ鑑別疾患をも網羅し，さらに画像医学や治療法の要点・トピックも掲載した．病理医はもちろん，臨床医の肝腫瘍に関する理解の一助としても役立つ1冊．50頁増の大幅改訂．

目次

  • 第1部　検鏡前の確認事項
    　I．肝癌組織分類の現状：肝癌取扱い規約とWHO分類から
    　　1．『原発性肝癌取扱い規約』による組織分類
    　　2．WHOによる組織分類
    　II．病理標本の取扱い方
    　　1．肝臓手術検体の処理法
    　　2．生検組織検体の処理方法
    　　3．ゲノム医療における病理組織検体の取扱い
    　III．肝癌の肉眼型診断
    　　1．肝細胞癌
    　　2．肝内胆管癌
    　IV．肝臓の解剖学・組織学
    　　1．肝臓の発生　
    　　2．肝臓の解剖
    　　3．肝臓の組織学

    第2部　組織型と診断の実際
    　I．肝細胞系腫瘍
    　　1．肝細胞癌
    　　2．早期肝細胞癌（dysplastic nodule, liver cell dysplasiaを含む）
    　　3．肝芽腫
    　　4．肝細胞癌の組織亜型
    　　　1．硬化型肝細胞癌
    　　　2．Fibrolamellar carcinoma
    　　　3．Steatohepatitic HCC
    　　　4．その他の亜型
    　　　5．肝細胞腺腫
    　II．胆管細胞系腫瘍
    　　1．肝内胆管癌（肝門部領域胆管癌を含む）
    　　2．細胆管細胞癌
    　　3．胆管内乳頭状腫瘍（IPNB）
    　　4．胆管内上皮内腫瘍（BilIN）
    　　5．粘液囊胞性腫瘍（MCN）
    　　6．胆管腺腫および類似病変
    　　7．Biliary adenofibroma
    　III．混合型肝癌および未分化癌
    　　1．混合型肝癌
    　　2．未分化癌
    　IV．神経内分泌腫瘍（NEN）
    　　1．NET，NEC
    　　2．混合型
    　V．腫瘍類似病変
    　　1．限局性結節性過形成
    　　2．その他の過形成性結節（結節性再生性過形成を含む）
    　　3．過誤腫
    　　　1．胆管性微小過誤腫
    　　　2．胆管周囲付属腺過誤腫
    　　　3．肝間葉系過誤腫
    　　　4．Multicystic biliary hamartoma
    　　　5．前腸性肝囊胞
    　　　6．その他の過誤腫性病変
    　　4．炎症性偽腫瘍/硬化性胆管炎
    　　5．肝内血行動態の変化に伴う偽病変・偽腫瘍
    　　　1．偽病変・偽腫瘍の定義
    　　　2．多血性偽病変
    　　　3．third inflow 流入部の偽病変
    　VI．血管・間葉系腫瘍およびその他
    　　1．血管腫/肝紫斑症
    　　　1．海綿状血管腫
    　　　2．硬化性血管腫
    　　　3．肝紫斑症
    　　2．血管肉腫/Hepatic small vessel neoplasm
    　　3．血管筋脂肪腫
    　　4．類上皮性血管内皮腫
    　　5．悪性リンパ腫および偽リンパ腫
    　　　1．悪性リンパ腫
    　　　2．偽リンパ腫
    　　6．その他
    　　　1．未分化胎児性肉腫
    　　　2．平滑筋肉腫
    　　　3．孤立性線維性腫瘍
    　　　4．胎児型横紋筋肉腫
    　　　5．その他の稀な間葉系良性腫瘍
    　　　6．その他の稀な間葉系悪性腫瘍
    　VII．転移性肝癌
    　　1．転移性肝癌と原発性肝癌との鑑別
    　　2．大腸癌肝転移における組織学的評価のポイント
    　　3．大腸癌肝転移に対する化学療法と化学療法関連肝障害

    第3部　鑑別ポイント
    　I．いわゆる境界病変の鑑別
    　　1．異型結節（DN）
    　　2．限局性脂肪化（FFC/FFL）
    　　3．限局性結節性過形成（FNH）およびFNH-like nodule
    　　4．血管筋脂肪腫（AML）
    　　5．肝細胞腺腫（HCA）
    　II．多発肝細胞癌における多中心性発生と肝内転移
    　III．腺癌の鑑別：偽腺管・硬化型，転移との鑑別
    　　1．胆管癌と鑑別を要する肝細胞癌
    　　2．胆管癌と鑑別を要する転移性肝癌
    　　3．胆管癌と鑑別を要する胆管病変
    　IV．肝門部胆管癌と肝内胆管癌の肝門部浸潤の鑑別
    　　1．肝門部領域癌に関する取扱いの現状
    　　2．腫瘍の主座を，詳細な切り出しと標本の観察で評価する
    　　3．肝門部に生じた腫瘍の評価方法
    　　4．問題点
    　V．免疫染色からみた鑑別診断
    　　1．上皮性腫瘍
    　　2．非上皮系腫瘍
    　　3．転移性腫瘍
    　　4．腫瘍類似病変
    　VI．腫瘍鑑別診断のポイントと限界
    　　１．生検組織診断の実際
    　　２．様々な診断困難例とその対処法
    　　３．良性肝細胞性病変の生検診断法：旧来の診断法と新診断法
    　　４．肝細胞性病変の様々な非定型例に対する対応法：個別化診断（三次元診断）

    第4部　臨床との連携
    　I．背景肝病変・臨床所見との対比
    　　1．年代別変遷
    　　2．病態と予後
    　II．代謝（メタボ）関連肝細胞癌
    　　1．非B非C肝細胞癌と代謝異常症
    　　2．メタボリック関連肝細胞癌の背景肝
    　　3．メタボリック関連肝細胞癌の臨床病理学的特徴
    　III．画像所見との対比
    　　1．画像検査の特徴と画像所見
    　　2．肝癌の画像所見
    　　3．胆管癌の画像所見
    　IV．治療効果判定
    　　1．肝癌の治療効果判定における病理の役割
    　　2．肝動脈塞栓療法（TAE）の病理像
    　　3．Ablation療法の適応と問題点
    　　4．エタノール注入療法（PEI）の病理像
    　　5．ラジオ波熱凝固療法（RFA）の病理像
    　　6．TAE 併用RFA 療法の病理像
    　　7．分子標的治療薬の病理像
    　V．病理診断報告書の記載：切除，生検
    　　1．申込書・依頼書
    　　2．病理診断報告書の実際

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1部 検鏡前の確認事項

P.4 掲載の参考文献
1) Gibson JB, Sobin LH : Histological typing of tumours of the liver, biliary tract and pancreas, World Health Organization International Histological Classification of Tumours. No. 20, Geneva, 1978
 
2) 村上文夫, 岡村純他 : 肝疾患の外科治療法. 診療 23 : 265-277, 1970
 
3) 石川浩一, 小坂淳夫 : 原発性肝癌切除例の手術成績. 肝臓 14 : 409-410, 1973
 
4) 石川浩一 : 原発性肝癌症例に関する追跡調査-第3報-. 肝臓 17 : 460-466, 1976
 
5) 日本肝癌研究会 : 原発性肝癌症例に関する追跡調査-第4報-. 肝臓 20 : 433-441, 1979
 
6) Okuda K. and The Liver Cancer Study Group of Japan : Primary liver cancers in Japan. Cancer 45 : 2663-2669, 1980
 
7) 日本肝癌研究会追跡調査委員会 : 第20回全国原発性肝癌追跡調査報告 (2008～2009), 肝臓 60 : 258-293, 2019
 
8) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第1版. 金原出版, 1983
 
9) Liver Cancer Study Group of Japan : Classification of Primary Liver Cancer. First English Edition. Kanehara & Co., Ltd., 1997
 
10) International Working Party : Terminology of nodular hepatocellular lesion. Hepatology 22, 983-993, 1995
 
11) Bosman FT, Carnerio F, Hruban RH et al : Tumours of the liver and intrahepatic bile ducts. in WHO Classification of Tumours of the Digestive System 4th ed. IARC, 2010
 
12) 神代正道 : 肝癌組織分類の現状 : 規約, WHO. 中沼安二, 坂元亨宇 (編), 腫瘍病理鑑別診断アトラス 肝癌. 文光堂, 2010, pp2-5
 
13) Brunt E, Aishima S, Clavien PA et al : cHCC-CCA : Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation. Hepatology 68 : 113-126, 2018
PubMed
14) Paradis V, Fukayama M, Park YN et al : Tumours of the liver and intrahepatic bile ducts. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019
 
P.13 掲載の参考文献
1) 尾島英知, 坂元亨宇 : 肝臓. 外科病理マニュアル, 病理と臨床 26 (臨増) : 160-167, 2008
 
2) 日本病理学会 (編) : ゲノム研究用・診療用病理組織検体取扱い規程. 羊土社, 2019
 
P.18 掲載の参考文献
1) Nakashima O, Sugihara S, Kage M et al : Pathomorphologic characteristics of small hepatocellular carcinoma : a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology 22 : 101-105, 1995
PubMed
2) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版補訂版. 金原出版, 2019
 
3) Eggel H : Uber das primare Carcinoma der Leber. Beitr Pathol Anat Allg Pathol 30 : 506-604, 1901
 
4) Ishak KG, Goodman ZD, Stocker JT : AFIP Atlas of Tumor Pathology 3rd Series, Fascicle 31 Tumors of the Liver and Intrahepatic Bile Ducts. American Registry of Pathology, 2001, pp199-244
 
P.26 掲載の参考文献
1) Collardeau-Frachon S, Scoazec JY : Vascular Development and differentiation during human liver organogenesis. Anat Rec 291 : 614-627, 2008
PubMed
2) Strazzabosco M, Fabris L : Development of the bile ducts : Essentials for the clinical hepatologist. J Hepatol 56 : 1159-1170, 2012
PubMed
3) Saba L, Mallarini G : Anatomic variations of arterial liver vascularization : an analysis by using MDCTA. Surg Radiol Anat 33 : 559-568, 2011
PubMed
4) Chaib E, Kanas AF, Galvao FHF et al : Bile duct confluence : anatomic variations and its classification. Surg Radiol Anat 36 : 105-109, 2014
 
5) Ben-Mashe S, Itzkovitz S : Spatial heterogeneity in the mammalian liver. Nat Rev Gastroenterol Hepatol 16 : 395-410, 2019
 
6) Desert R, Rohart F, Canal F et al : Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology 66 : 1502-1518, 2017
PubMed
7) Strauss O, Phillips A, Ruggiero K et al : Immunofluorescence identifies distinct subsets of endothelial cells in the human liver. Sci Rep 7 : 44356, 2017
PubMed
8) Lepreux S, Bioulac-Sage P, Gabbiani G et al : Cellular retinol-binding protein-1 expression in normal and fibrotic/cirrhotic human liver : different patterns of expression in hepatic stellate cells and (myo) fibroblast subpopulations. J Hepatol 40 : 774-780, 2004
PubMed
9) Nakanuma Y, Hoso M, Sanzen T et al : Microstructure and development of the normal and pathologic biliary tract in humans, including blood supply. Microsc Res Tech 38 : 552-570, 1997
PubMed
10) Overi D, Carpino G, Cardinale V et al : Contribution of resident stem cells to liver and biliary tree regeneration in human diseases. Int J Mol Sci 19 : 2018
 
11) Aishima S, Oda Y : Pathogenesis and classification of intrahepatic cholangiocarcinoma : Different characters of perihilar large duct type versus peripheral small duct type. J Hepatobiliary Pancreat Sci 22 : 94-100, 2015
PubMed

第2部 組織型と診断の実際

P.41 掲載の参考文献
1) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版補訂版, 金原出版, 2019
 
2) Torbenson MS, Ng IOL, Park YN et al : Hepatocellular carcinoma. in WHO Classification of Tumours Editrial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours IARC, 2019 pp229-239
 
3) Hirohashi S, Ishak KG, Kojiro M et al : Hepatocellular carcinoma. in Hamilton SR, Aaltonen LA (eds), WHO Classification of Tumors. Pathology and Genetics of Tumors of the Digestive System. IARC, 2000 pp159-72
 
4) Kojiro M : Pathology of hepatocellular carcinoma. Blackwell Pub, 2006.
 
5) Kin M, Torimura T, Ueno T et al : Sinusoidal capillarization in small hepatocellular carcinoma. Pathol Int 44 : 771-778, 1994
PubMed
6) 日本肝臓学会 : 肝がん白書 平成27年度. 日本肝臓学会, 2015
 
7) Oikawa T, Ojima H, Yamasaki S et al : Multistep and multicentric development of hepatocellular carcinoma : histological analysis of 980 resected nodules. J Hepatol 42 : 225-229, 2005
PubMed
8) Sakamoto M, Hirohashi S, Shimosato Y : Early stages of multistep hepatocarcinogenesis : adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 22 : 172-178, 1991
PubMed
9) International Consensus Group for Hepatocellular Neoplasia : Pathologic diagnosis of early hepatocellular carcinoma : A report of the international consensus group for hepatocellular neoplasia. Hepatology 49 : 658-664, 2009
 
10) Fujimoto A, Totoki Y, Abe T et al : Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 44 : 760-764, 2012
PubMed
11) Zucman-Rossi J, Villanueva A, Nault JC et al : Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology 149 : 1226-1239, 2015
PubMed
12) Cancer Genome Atlas Research Network. Electronic address : wheeler@bcm.edu ; Cancer Genome Atlas Research Network : Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma. Cell 169 : 1327-1341, 2017
 
13) Nault JC, Martin Y, Caruso S et al : Clinical impact of genomic diversity from early to advanced hepatocellular carcinoma. Hepatology 71 : 164-182, 2020
PubMed
14) Nault JC, Galle PR, Marquardt JU : The role of molecular enrichment on future therapies in hepatocellular carcinoma. J Hepatol 69 : 237-247, 2018
PubMed
15) Hsu IC, Metcalf RA, Sun T et al : Mutational hotspot in the p53 gene in human hepatocellular carcinoma. Nature 350 : 427-428, 1991
PubMed
16) Lan KH, Sheu ML, Hwang SJ et al : HCV NS5A interacts with p53 and ihhibits p53-mediated apotosis. Oncogene 21 4801-4811, 2002
 
17) 坂元亨宇, 鹿毛政義 (編) : 肝生検診断 I-腫瘍性疾患-. 病理と臨床 23 : 120-172, 2005
 
18) Chu PG, Ishizawa S, Wu E et al : Hepatocyte antigen as a marker of hepatocellular carcinoma : an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol 26 : 978-988, 2002
PubMed
19) Chuma M, Sakamoto M, Yamazaki K et al : Expression profiling in multistage hepatocarcinogenesis : identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 37 : 198-207, 2003
PubMed
20) Di Tommaso L, Franchi G, Park YN et al : Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 45 : 725-734, 2007
PubMed
21) Di Tommaso L, Destro A, Seok JY et al : The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 50 : 746-754, 2009
PubMed
22) Uenishi T, Kubo S, Yamamoto T et al : Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci 94 : 851-857, 2003
PubMed
23) Tsuchiya K, Komuta M, Yasui Y et al : Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology 80 : 278-288, 2011
PubMed
24) Kim H, Choi GH, Na DC et al : Human hepatocellular carcinomas with "Stemness" -related marker expression : keratin 19 expression and a poor prognosis. Hepatology 54 : 1707-1717, 2011
 
25) Tsujikawa H, Masugi Y, Yamazaki K et al : Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness. Hum Pathol 50 : 24-33, 2016
PubMed
26) Hoshida Y, Toffanin S, Lachenmayer A et al : Molecular classification and novel targets in hepatocellular carcinoma : recent advancements. Semin Liver Dis 30 : 35-51, 2010
PubMed
27) Boyault S, Rickman DS, de Reynies A et al : Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45 : 42-52, 2007
PubMed
28) Chiang DY, Villanueva A, Hoshida Y et al : Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 68 : 6779-6788, 2008
PubMed
29) Ueno A, Masugi Y, Yamazaki K et al : Precision pathology analysis of the development and progression of hepatocellular carcinoma : Implication for precision diagnosis of hepatocellular carcinoma. Pathol Int 70 : 140-154, 2020
PubMed
30) Kurebayashi Y, Ojima H, Tsujikawa H et al : Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology 68 : 1025-1041, 2018
PubMed
31) Renne SL, Woo HY, Allegra S et al : Vessels encapsulating tumor clusters (VETC) is a powerful predictor of aggressive hepatocellular carcinoma. Hepatology 71 : 183-195, 2020
PubMed
P.47 掲載の参考文献
1) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第3版. 金原出版, 1992
 
2) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第4版. 金原出版, 2000
 
3) ICGHN International Consensus Group for Hepatocellular Neoplasia : Pathologic diagnosis of early hepatocellular carcinoma : a report of the international consensus group for hepatocellular neoplasia. Hepatology 49 : 658-664, 2009
 
4) 中野雅行, 斉藤明子, 高崎健他 : 超高分化型肝細胞癌の門脈域 (グ鞘) 浸潤. 肝臓 31 : 218-219, 1990
 
5) 中野雅行, 斉藤明子, 高崎健他 : 初期肝細胞癌の発育・進展の病理. 肝臓31 : 754-761, 1990
 
6) 南麻紀子, 松井修 : 肝癌の多段階発癌のCTHA/CTAPによる描出. 肝胆膵画像 11 : 11-16, 2009
 
7) 今井康陽, 小来田幸世, 高村学他 : EOB-MRI : CTAP, SPIO-MRIとの比較. 肝胆膵画像 14 : 330-338, 2012
 
8) 松井修, 北尾梓, 小林 聡他 : 早期肝細胞癌 (肝癌多段階発癌) の画像診断. 肝臓 52 : 415-428, 2011
 
9) 田中三千雄 : 序説 われわれは知っているものだけを見る. 消化器内視鏡 24 : 1694-1695, 2012
Medical*Online
10) International Working Party : Terminology of nodular hepatocellular lesions. Hepatology 22 : 983-993, 1995
PubMed
11) 中野雅行 : 超高分化型肝細胞癌について. 癌の臨床 44 : 520-524, 1998
Medical*Online
12) 中野雅行 : 癌細胞の間質浸潤に関する最近の知見と考察-分化型肝細癌をもとにして. 病理と臨床 15 : 739-742, 1997
 
13) 中野雅行 : 肝細胞癌の前癌病変および境界病変 肝癌の診断と治療 最新の研究動向. 日本臨牀 59 (増刊号 6) : 216-221, 2001
 
14) 中野雅行 : 高分化型肝細胞癌の画像解析による組織診断核の円形度の有用性について. 肝臓 31 : 318-323, 1990
 
15) Nakano M, Saito A, Yamamoto M et al : Stromal and blood vessel wall invasion in well-differentiated hepatocellular carcinoma. Liver 17 : 41-46, 1997
PubMed
16) Okazaki I, Wada N, Nakano M et al : Difference in gene expression For Matrix Metalloproteinase-1 between early and advanced hepatocellular carcinomas. Hepatology 25 : 580-584, 1997
PubMed
17) 中野雅行 : 早期肝細胞癌の病理診断-門脈域未浸潤の早期肝細胞癌 : Preinvasive early HCC 肝臓フォーラム東部 2011 (第24回肝臓フォーラム東部記録集) : 46-62, 2011
 
18) tremosini S, Forner A, Boix L et al : Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 61 : 1481-1487, 2012
PubMed
19) Tommaso LD, Destro A, Fabbris V et al : Diagnostic accuracy of clathrin heavy chain staining in a marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 53 : 1549-1557, 2011
 
20) Cai MY, Tong ZT, Zheng F et al : EZH2 protein : a promising immunomarker for the detection in needle biopsies. Gut 60 : 967-976, 2011
PubMed
21) Sciarra A, Tommaso LD, Nakano M et al : Morphophenotypic changes in human multistep hepatocarcinogenesis with translational implications. J Hepatology 64 : 87-93, 2016
 
22) Park NY, Kojiro M, Tommaso LD et al : Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules. Cancer 109 : 915-923, 2007
 
P.53 掲載の参考文献
1) Torvenson M, Yoh Zen, Matthew M : Hepatoblastoma, AFIP Atlas of Tumor Pathology Series 4, Fascicle 27 Tumors of the Liver. American Registry of Pathology, 2018, pp117-132
 
2) Saxena R, Quaglia A : Hepatoblastoma. in WHO Classification of Tumours Editrial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp240-244
 
3) 日本小児外科学会悪性腫瘍委員会 : 小児の外科的悪性腫瘍, 2017年登録症例の全国集計結果の報告. 日本小児外科学会雑誌 55 : 135-173, 2019
Medical*Online
4) Duan XF, Zhao Q : Adult hepatoblastoma : a review of 47 cases. ANZ J Surg 88 : E50-E54, 2018
PubMed
5) 神澤真紀, 堀江靖 : 成人肝芽腫の1例. 診断病理 27 : 294-297, 2010
Medical*Online
6) Tanimura M, Matsui I, Abe J et al : Increased risk of hepatoblastoma among immature children with a lower birth weight. Cancer Res, 58 : 3032-3035, 1998
PubMed
7) 別所文雄 : 肝芽腫 低出生体重児における発生について. 日本新生児成育医学会雑誌 29 : 22-27, 2017
Medical*Online
8) 菱木知郎, 川久保尚徳 : 【小児のがん-最近の動向】肝芽腫. 小児科 60 : 1045-1056, 2019
 
9) 宮嵜治 : 【小児のがん-最近の動向】小児がんの画像診断. 小児科 60 : 1067-1074, 2019
 
10) Lopez-Terrada D, Alaggio R, deDavila MT et al : Towards an international pediatric liver tumor consensus classification : proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol 27 : 472-491, 2014
 
11) Fasano M, Theise ND, Naleskin M et al : Immunohistochemical evaluation of hepatoblastomas with use of the hepatocyte-specific marker, hepatocyte paraffin 1, and the polyclonal anti-carcinoembryonic antigen. Mod Pathol 11 : 934-938, 1998
 
12) Koch A, Denkhaus D, Albrecht S : Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 59 : 269-273, 1999
PubMed
13) 大喜多肇 : 【癌の分子病理学 病理診断から治療標的探索まで】 (第2部) 癌の分子病理学 臓器癌 小児腫瘍. 病理と臨床 34 臨時増刊 : 263-270, 2016
 
14) Albrecht S, vonSchweinitz D, Waha A et al : Loss of maternal alleles on chromosome arm 11p in hepatoblastoma. Cancer Res 54 : 5041-5044, 1994
 
P.62 掲載の参考文献
1) Torbenson M, Ng I, Park Y, Roncalli M, Sakamoto M : Hepatocellular carcinoma. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 229-239, 2019
 
2) Torbenson M, Zen Y, Yeh MM : Hepatocellular carcinoma. AFIP Atlas of Tumor Pathology Series 4, Fascicle 27 Tumors of the Liver. American Registry of Pathology, 39-96, 2018
 
3) 尾島英知 : Fibrolamellar hepatocellular carcinomaと硬化型肝細胞癌の臨床病理学的特徴と諸問題 : 病理診断医間に存在する硬化型肝細胞癌組織診断基準の差異に関する現状報告も兼ねて. Liver Cancer 15 : 1-8, 2009
Medical*Online
4) Lee JH, Choi MS, Gwak GY et al : Clinicopathologic characteristics and long-term prognosis of scirrhous hepatocellular carcinoma. Dig Dis Sci 57 : 1698-1707, 2012
PubMed
5) Kim H, Park YN : Hepatocellular carcinomas expressing 'stemness' -related markers : clinicopathological characteristics. Dig Dis 32 : 778-785, 2014
PubMed
6) Hatano M, Ojima H, Masugi Y et al : Steatotic and nonsteatotic scirrhous hepatocellular carcinomas reveal distinct clinicopathological features. Hum Pathol 86 : 222-232, 2019
PubMed
7) Seok JY, Na DC, Woo HG et al : A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. Hepatology 55 : 1776-1786, 2012
PubMed
8) Torbenson M, Zen Y, Yeh MM : Fibrolamellar carcinoma., AFIP Atlas of Tumor Pathology Series 4, Fascicle 27 Tumors of the Liver. American Registry of Pathology, 97-116, 2018
 
9) Darcy DG, Malek MM, Kobos R et al : Prognostic factors in fibrolamellar hepatocellular carcinoma in young people. J Pediatr Surg 50 : 153-156, 2015
 
10) Pinna AD, Iwatsuki S, Lee RG et al : Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology 26 : 877-883, 1997
PubMed
11) Honeyman JN, Simon EP, Robine N et al : Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science 343 : 1010-1014, 2014
PubMed
12) Salomao M, Yu WM, Brown RS Jr et al : Steatohepatitic hepatocellular carcinoma (SH-HCC) : a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 34 : 1630-1636, 2010
 
13) Salomao M, Remotti H, Vaughan R et al : The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 43 : 737-746, 2012
PubMed
14) Shibahara J, Ando S, Sakamoto Y et al : Hepatocellular carcinoma with steatohepatitic features : a clinicopathological study of Japanese patients. Histopathology 64 : 951-962, 2014
PubMed
15) Taniai M, Hashimoto E, Tobari M et al : Clinicopathological investigation of steatohepatitic hepatocellular carcinoma : A multicenter study using immunohistochemical analysis of adenoma-related markers. Hepatol Res 48 : 947-955, 2018
PubMed
16) Ando S, Shibahara J, Hayashi A et al : Beta-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features : immunohistochemical and mutational study. Virchows Arch 467 : 535-542, 2015
PubMed
17) Calderaro J, Couchy G, Imbeaud S et al : Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. J Hepatol 67 : 727-738, 2017
PubMed
18) Ziol M, Pote N, Amaddeo G et al : Macrotrabecular-massive hepatocellular carcinoma : A distinctive histological subtype with clinical relevance. Hepatology 68 : 103-112, 2018
PubMed
19) Li T, Fan J, Qin LX et al : Risk factors, prognosis, and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol 18 : 1955-1963, 2011
PubMed
20) Wood LD, Heaphy CM, Daniel HD et al : Chromophobe hepatocellular carcinoma with abrupt anaplasia : a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features. Mod Pathol 26 : 1586-1593, 2013
PubMed
21) Torbenson MS : Morphologic subtypes of hepatocellular carcinoma. Gastroenterol Clin North Am 46 : 365-391, 2017
PubMed
P.68 掲載の参考文献
1) Bioulac-Sage P, Kakar S, Nault JC : Hepatocellular adenoma. in WHO Classification of the Tumours Editorial Board (ed.), WHO Classification of the Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp224-228
 
2) Torbenson M, Zen Y, Yeh MM : AFIP Atlas of Tumor Pathology series 4, Fascicle 27 Tumors of the Liver. American Registry of Pathology, 2018, pp22-35
 
3) Goodman ZD, Terracciano LM : Tumours and tumour-like lesions of the liver. in Burt AD, Portmann BC, Ferrell LD (eds), MacSween's Pathology of the Liver 7th ed. Elsevier, 2018, pp785-793
 
4) Nault JC, Paradis V, Cherqui D et al : Molecular classification of hepatocellular adenoma in clinical practice. J Hepatol 67 : 1074-1083, 2017
PubMed
5) Nault JC, Couchy G, Caruso S et al : Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. Hepatology 68 : 103-112, 2018
 
6) Nault JC, Couchy G, Balabaud C et al : Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology 152 : 880-894, 2017
PubMed
7) Fukusato T, Soejima Y, Kondo F et al : Preserved or enhanced OATP1B3 expression in hepatocellular adenoma subtypes with nuclear accumulation of β-catenin. Hepatol Res 45 : E32-E42, 2015
 
8) 副島友莉恵, 福里利夫, 斎藤光次他 : 肝細胞腺腫亜型の臨床的および病理学的特徴-本邦経験例と欧米例の比較検討-. Liver Cancer 22 : 35-39, 2016
 
9) Van Aalten SM, Verheij J, Terkivatan T et al : Validation of a liver adenoma classification system in a tertiary referral centre : implications for clinical practice. J Hepatol 55 : 120-125, 2011
 
10) Bellamy CO, Maxwell RS, Prost S et al : The value of immunophenotyping hepatocellular adenomas : consecutive resections at one UK centre. Histopathology 62 : 431-445, 2013
PubMed
11) Huang WC, Liau JY, Jeng YM et al : Hepatocellular adenoma in Taiwan : Distinct ensemble of male predominance, overweight/obesity, and inflammatory subtype. J Gastroenterol Hepatol 2019 Nov 7. doi : 10.1111/jgh.14903. [Epub ahead of print]
 
12) Sciarra A, Schmidt S, Pellegrinelli A et al : OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. Liver Int 39 : 158-167, 2019
PubMed
13) 近藤福雄, 副島友莉恵, 福里利夫 : 良性肝細胞性結節の病理診断 : 新WHO 分類をふまえて. 肝臓 54 : 807-818, 2013
 
P.82 掲載の参考文献
1) Nakanuma Y, Klimstra DS, Komuta M et al : Intrahepatic cholangiocarcinoma. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours IARC, 2019, pp254-259
 
2) Nakeeb A, Pitt HA, Sohn TA et al : Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 224 : 463-473, 1996
PubMed
3) Razumilava N, Gores GJ : Cholangiocarcinoma. Lancet 383 : 2168-79, 2014
PubMed
4) Zen Y, Hubscher SG, Nakanuma Y : Bile duct diseases. in Burt AD, Ferrell LD, Hubscher SG (eds), MacSween's Pathology of the Liver 7th ed. Churchill Livingstone 2018, pp515-593
 
5) Roa JC, Adsay NV, Arola J et al : Carcinoma of the extrahepatic bile ducts. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours IARC, 2019, pp289-291
 
6) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版. 金原出版, 2015
 
7) 日本肝胆膵外科学会 (編) : 臨床・病理 胆道癌取扱い規約 第6版. 金原出版, 2013
 
8) Nakanuma Y, Hoso M, Sanzen T et al : Microstructure anddevelopment of the normal and pathologic biliary tract in humans, including blood supply. Microsc Res Tech 38 : 552-570, 1997
 
9) Nakanuma Y, Kakuda Y : Pathologic classification of cholangiocarcinoma : New concepts. Best Pract Res Clin Gastroenterol 29 : 277-293, 2015
PubMed
10) Deoliveira ML, Schulick RD, Nimura Y et al : New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 53 : 1363-1371, 2011
 
11) Akita M, Fujikura K, Ajiki T et al : Dichotomy in intrahepatic cholangiocarcinomas based on histologic similarities to hilar cholangiocarcinomas. Mod Pathol 30 : 986-997, 2017
PubMed
12) Akita M, Sofue K, Fujikura K et al : Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma. HPB (Oxford) 21 : 226-234, 2019
PubMed
13) Sia D, Hoshida Y, Villanueva A et al : Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 144 : 829-840, 2013
PubMed
14) Hayashi A, Misumi K, Shibahara J et al : Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma. Am J Surg Pathol 40 : 1021-1030, 2016
PubMed
15) Okuda K, Nakanuma Y, Miyazaki M : Cholangiocarcinoma : recent progress. Part 1 Epidemiology and etiology. J Gastroenterol Hepatol 17 : 1049-1055, 2002
PubMed
16) Yamasaki S : Intrahepatic cholangiocarcinoma : macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 10 : 288-291, 2003
PubMed
17) Ikai I, Arii S, Okazaki M et al : Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 37 : 676-691, 2007
PubMed
18) Ying S, Ying M, Liang W et al : Morphological classification of intraductal papillary neoplasm of the bile duct. Eur Radiol 28 : 1568-1578. 2018
PubMed
19) Nakanuma Y, Kakuda Y, Uesaka K : Characterization of intraductal papillary neoplasm of the bile duct with respect to the histopathologic similarities to pancreatic intraductal papillary mucinous neoplasm. Gut Liver 13 : 617-627, 2019
 
20) Terada T, Nakanuma Y : Pathological observations of intrahepatic peribiliary glands in 1,000 consecutive autopsy livers. II A possible source of cholangiocarcinoma. Hepatology 12 : 92-97, 1990
 
21) Farshidfar F, Zheng S, Gingras MC et al : Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep 19 : 2878-2880, 2017
 
22) Gandou C, Harada K, Sato Y et al : Hilar cholangiocarcinoma and pancreatic ductal adenocarcinoma share similar histopathologies, immunophenotypes, and development-related molecules. Hum Pathol 44 : 811-821, 2013
PubMed
23) Nakanuma Y : A novel approach to biliary tract pathology based on similarities to pancreatic counterparts : is the biliary tract an incomplete pancreas? Pathol Int 60 : 419-429, 2010
PubMed
24) Theise N, Nakajima O, Park YN et al : Combined hepatocellular-cholangiocarcinoma. in Bosman FT, Carneiro F, Hruban RH et al (eds), WHO Classification of Tumours of the Digestive System 4th ed. IARC, 2010, pp225-227
 
25) Nakanuma Y, Sato Y, Ikeda H et al : Intrahepatic cholangiocarcinoma with predominant "ductal plate malformation" pattern : a new subtype. Am J Surg Pathol 36 : 1629-1635, 2012
PubMed
26) Harewood GC, Baron TH, Stadheim LM et al : Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation. Am J Gastroenterol 99 : 1464-1469, 2004
PubMed
27) Kipp BR, Stadheim LM, Halling SA et al : A comparison of routine cytology and fluorescence in situ hybridization for the detection of malignant bile duct strictures. Am J Gastroenterol 99 : 1675-1681, 2004
PubMed
28) Khan SA, Tavolari S, Brandi G : Cholangiocarcinoma : Epidemiology and risk factors. Liver Int 39 Suppl 1 : 19-31, 2019
 
29) Kubo S, Nakanuma Y, Takemura S et al : Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan. J Hepatobiliary Pancreat Sci 21 : 479-488, 2014
PubMed
30) Tomimatsu M, Ishiguro N, Taniai M et al : Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer 72 : 683-688, 1993
PubMed
31) Kim SJ, Akita M, Sung YN et al : MDM2 amplification in intrahepatic cholangiocarcinomas : Its relationship with large-duct type morphology and uncommon KRAS mutations. Am J Surg Pathol 42 : 512-521. 2018
PubMed
32) Moeini A, Sia D, Bardeesy N et al : Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma. Clin Cancer Res 22 : 291-300, 2016
PubMed
33) Akita M, Sofue K, Fujikura K et al : Histological and molecular characterization of intrahepatic bile duct cancers suggests an expanded definition of perihilar cholangiocarcinoma HPB (Oxford) 21 : 226-234 2019
PubMed
34) Shibata T, Arai Y, Totoki Y : Molecular genomic landscapes of hepatobiliary cancer. Cancer Sci 109 : 1282-1291, 2018
PubMed
35) Ohira S, Sasaki M, Harada K et al : Possible regulation of migration of intrahepatic cholangiocarcinoma cells by interaction of CXCR4 expressed in carcinoma cells with tumor necrosis factor-alpha and stromal-derived factor-1 released in stroma. Am J Pathol 168 : 1155-1168, 2006
PubMed
P.88 掲載の参考文献
1) Komuta M, Spee B, Vander Borght S et al : Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin. Hepatology 47 : 1544-1556, 2008
 
2) Steiner PE, Higginson J : Cholangiolocellular carcinoma of the liver. Cancer 12 : 753-759, 1959
PubMed
3) Roskams TA, Libbrecht L, Desmet VJ : Progenitor cells in diseased human liver. Semin Liver Dis 23 : 385-396, 2003
PubMed
4) Theise ND, Saxena R, Portmann BC et al : The canals of Hering and hepatic stem cells in humans. Hepatology 30 : 1425-1433, 1999
PubMed
5) Roskams TA, Theise ND, Balabaud C et al : Nomenclature of the finer branches of the biliary tree : canals, ductules, and ductular reactions in human livers. Hepatology 39 : 1739-1745, 2004
PubMed
6) Moeini A, Sia D, Zhang Z et al : Mixed hepatocellular cholangiocarcinoma tumors : Cholangiolocellular carcinoma is a distinct molecular entity. J Hepatol 66 : 952-961, 2017
PubMed
7) Sasaki M, Sato Y, Nakanuma Y : Cholangiolocellular carcinoma with "ductal plate malformation" pattern may be characterized by ARID1A genetic alterations. Am J Surg Pathol 43 : 352-360, 2019
PubMed
8) Komuta M, Yeh MM : A review on the update of combined hepatocellular cholangiocarcinoma. Semin Liver Dis 2019
PubMed
9) Kurogi M, Nakashima O, Miyaaki H et al : Clinicopathological study of scirrhous hepatocellular carcinoma. J Gastroenterol Hepatol 21 : 1470-1477, 2006
PubMed
10) Govaere O, Petz M, Wouters J et al : The PDGFR α-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene 36 : 6605-6616, 2017
 
P.97 掲載の参考文献
1) Chen TC, Nakanuma Y, Zen Y et al : Intraductal papillary neoplasia of the liver associated with hepatolithiasis. Hepatology 34 (4 Pt 1) : 651-658, 2001
PubMed
2) Nakanuma Y, Franceschi CM, Gores S et al : Intrahepatic cholangiocarcinoma. in Bosman FT, Carneiro F, Hruban RH, et al (eds), WHO Classification of Tumours of the Digestive System 4th ed. IARC, 2010, pp 217-224
 
3) Nakanuma Y, BO, Esposito I et al : Intraductal papillary neoplasm of the bile ducts. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp 279-282
 
4) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版補訂版. 金原出版, 2019
 
5) Fujikura K, Fukumoto T, Ajiki T et al : Comparative clinicopathological study of biliar y intraductal papillary neoplasms and papillary cholangiocarcinomas. Histopathology 69 : 950-961, 2016
 
6) Nakanuma Y, Jang KT, Fukushima N et al : A statement by the Japan-Korea expert pathologists for future clinicopathological and molecular analyses toward consensus building of intraductal papillary neoplasm of the bile duct through several opinions at the present stage. J Hepatobiliary Pancreat Sci 25 : 181-187, 2018
 
7) Albores-Saavedra J, Murakata L, Krueger JE et al : Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts. Cancer 89 : 508-515, 2000
PubMed
8) Gordon-Weeks AN, Jones K, Harriss E et al : Systematic Review and Meta-analysis of Current Experience in Treating IPNB : Clinical and Pathological Correlates. Ann Surg 263 : 656-663, 2016
PubMed
9) Fukumura Y, Nakanuma Y, Kakuda Y et al : Clinicopathological features of intraductal papillary neoplasms of the bile duct : a comparison with intraductal papillary mucinous neoplasm of the pancreas with reference to subtypes. Virchows Arch 471 : 65-76, 2017
PubMed
10) Nakanuma Y, Kakuda Y, Uesaka K : Characterization of intraductal papillary neoplasm of the bile duct with respect to the histopathologic similarities to pancreatic intraductal papillary mucinous neoplasm. Gut Liver 13 : 617-627, 2019
 
11) Yang CY, Huang WJ, Tsai JH et al : Targeted next-generation sequencing identifies distinct clinicopathologic and molecular entities of intraductal papillary neoplasms of the bile duct. Mod Pathol 32 : 1637-1645, 2019
PubMed
12) Nakanuma Y, Kakuda Y, Fukumura Y et al : The pathologic and genetic characteristics of the intestinal subtype of intraductal papillary neoplasms of the bile duct. Am j surg pathol 43 : 1212-1220, 2019
PubMed
13) Schlitter AM, Born D, Bettstetter M et al : Intraductal papillary neoplasms of the bile duct : stepwise progression to carcinoma involves common molecular pathways. Mod Pathol 27 : 73-86, 2014
PubMed
P.101 掲載の参考文献
1) Basturk O, Aishima S, Esposito I : Biliary intraepithelial neoplasia. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp273-275
 
2) Zen Y, Adsay NV, Bardadin K et al : Biliary intraepithelial neoplasia : an international interobserver agreement study and proposal for diagnostic criteria. Mod Pathol 20 : 701-709, 2007
PubMed
3) Nakanuma Y, Klimstra DS, Komuta M et al : Intrahepatic cholangiocarcinoma. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp254-259
 
4) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版補訂版. 金原出版, 2019
 
5) 日本肝胆膵外科学会 (編) : 臨床・病理 胆道癌取扱い規約 第6版. 金原出版, 2013
 
6) Aishima S, Kuroda Y, Nishihara Y et al : Proposal of progression model for intrahepatic cholangiocarcinoma : clinicopathologic differences between hilar type and peripheral type. Am J Surg Pathol 31 : 1059-1067, 2007
PubMed
7) Matthaei H, Lingohr P, Strasser A et al : Biliary intraepithelial neoplasia (BilIN) is frequently found in surgical margins of biliary tract cancer resection specimens but has no clinical implications. Virchows Arch 466 : 133-141, 2015
PubMed
8) Aishima S, Fujita N, Mano Y et al : Different roles of S100P overexpression in intrahepatic cholangiocarcinoma : carcinogenesis of perihilar type and aggressive behavior of peripheral type. Am J Surg Pathol 35 : 590-598, 2011
PubMed
9) Sato Y, Sasaki M, Harada K et al : Pathological diagnosis of flat epithelial lesions of the biliary tract with emphasis on biliary intraepithelial neoplasia. J Gastroenterol 49 : 64-72, 2014
PubMed
10) Nakanishi Y, Zen Y, Kondo S et al : Expression of cell cycle-related molecules in biliary premalignant lesions : biliary intraepithelial neoplasia and biliary intraductal papillary neoplasm. Hum Pathol 39 : 1153-1161, 2008
PubMed
11) Sasaki M, Yamaguchi J, Itatsu K et al : Over-expression of polycomb group protein EZH2 relates to decreased expression of p16 INK4a in cholangiocarcinogenesis in hepatolithiasis. J Pathol 215 : 175-183, 2008
PubMed
12) Nakanuma Y, Basturk O, Esposito I : Intraductal papillary neoplasm of the bile ducts. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp279-282
 
13) Sato Y, Harada K, Sasaki M et al : Histological characteristics of biliary intraepithelial neoplasia-3 and intraepithelial spread of cholangiocarcinoma Virchows Arch 462 : 421-427, 2013
PubMed
14) Hsu M, Sasaki M, Igarashi S et al : KRAS and GNAS mutations and p53 overexpression in biliary intraepithelial neoplasia and intrahepatic cholangiocarcinomas. Cancer 119 : 1669-1674, 2013
PubMed
15) Kubo Y, Aishima S, Tanaka Y et al : Differential expression of glucose transporters in the progression of intrahepatic cholangiocarcinoma. Hum Pathol 45 : 1610-1617, 2014
 
16) Sasaki M, Nitta T, Sato Y et al : Autophagy may occur at an early stage of cholangiocarcinogenesis via biliary intraepithelial neoplasia. Hum Pathol 46 : 202-209, 2015
PubMed
P.107 掲載の参考文献
1) WHO Classification of Tumours Editrial Board (ed.) : WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019
 
2) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版補訂版. 金原出版, 2019
 
3) Wheeler DA, Edmondson HA : Cystadenoma with mesenchymal stroma (CMS) in the liver and bile ducts. A clinicopathologic study of 17 cases, 4 with malignant change. Cancer 56 : 1434-1445, 1985
PubMed
4) Devaney K, Goodman ZD, Ishak KG : Hepatobiliary cystadenoma and cystadenocarcinoma. A light microscopic and immunohistochemical study of 70 patients. Am J Surg Pathol 18 : 1078-1091, 1994
PubMed
5) Zen Y, Jang KT, Ahn S et al : Intraductal papillary neoplasms and mucinous cystic neoplasms of the hepatobiliary system : demographic differences between Asian and Western populations, and comparison with pancreatic counterparts. Histopathology. 65 : 164-173, 2014
PubMed
6) Quigley B, Reid MD, Pehlivanoglu B et al : Hepatobiliary mucinous cystic neoplasms with ovarian type stroma (so-called "hepatobiliary cystadenoma/cystadenocarcinoma") : clinicopathologic analysis of 36 cases illustrates rarity of carcinomatous change. Am J Surg Pathol. 42 : 95-102, 2018
PubMed
7) Mavilia MG, Pakala T, Molina M et al : Differentiating cystic liver lesions : a review of imaging modalities, diagnosis and management. J Clin Transl Hepatol. 6 : 208-216, 2018
PubMed
8) Zhelnin K, Xue Y, Quigley B et al : Nonmucinous biliary epithelium is a frequent finding and is often the predominant epithelial type in mucinous cystic neoplasms of the pancreas and liver. Am J Surg Pathol. 41 : 116-120, 2017
PubMed
9) 近藤福雄 : 診断困難例および疾患概念や診断基準の問題点. 肝胆膵 52 : 243-249, 2006
Medical*Online
10) Fujikura K, Akita M, Abe-Suzuki S et al : Mucinous cystic neoplasms of the liver and pancreas : relationship between KRAS driver mutations and disease progression. Histopathology. 71 : 591-600, 2017
PubMed
11) Kumata H, Murakami K, Ishida K et al : Steroidogenesis in ovarian-like mesenchymal stroma of hepatic and pancreatic mucinous cystic neoplasms. Hepatol Res. 2018 ; 48 : 989-999.
PubMed
12) Kishida N, Shinoda M, Masugi Y, et al : Cystic tumor of the liver without ovarian-like stroma or bile duct communication : two case reports and a review of the literature. World J Surg Oncol. 12 : 229, 2014
PubMed
13) Hsu M, Terris B, Wu TT, et al : Endometrial cysts within the liver : a rare entity and its differential diagnosis with mucinous cystic neoplasms of the liver. Hum Pathol. 2014 ; 45 : 761-7.
PubMed
14) Labib PLZ, Aroori S, Bowles M et al : Differentiating Simple Hepatic Cysts from Mucinous Cystic Neoplasms : Radiological Features, Cyst Fluid Tumour Marker Analysis and Multidisciplinary Team Outcomes. Dig Surg. 2017 ; 34 : 36-42.
 
15) Wheeler DA, Edmondson HA : Ciliated hepatic foregut cyst. Am J Surg Pathol 8 : 467-470, 1984
PubMed
16) Nakanuma Y, Kurumaya H, Ohta G : Multiple cysts in the hepatic hilum and their pathogenesis. A suggestion of periductal gland origin. Virchows Arch A Pathol Anat Histopathol 404 : 341-350, 1984
PubMed
17) Zen Y, Terahata S, Miyayama S et al : Multicystic biliary hamartoma : a hitherto undescribed lesion. Hum Pathol 37 : 339-344, 2006
PubMed
P.113 掲載の参考文献
1) Tsui W, Nakanuma Y : Bile duct adenoma. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019
 
2) Allaire GS, Rabin L, Ishak KG et al : Bile duct adenoma. A study of 152 cases. Am J Surg Pathol 12 : 708-715, 1988
PubMed
3) Bhathal PS, Hughes NR, Goodman ZD : The so-called bile duct adenoma is a peribiliary gland hamartoma. Am J Surg Pathol 20 : 858-864, 1996
PubMed
4) Pujals A, Bioulac-Sage P, Castain C et al : BRAF V600E mutational status in bile duct adenomas and hamartomas. Histopathology 67 : 562-567, 2015
PubMed
5) O'hara BJ, McCue PA, Miettinen M : Bile duct adenomas with endocrine component. Immunohistochemical study and comparison with conventional bile duct adenomas. Am J Surg Pathol 16 : 21-25, 1992
PubMed
6) Sasaki M, Ikeda H, Nakanuma Y : Expression profiles of MUC mucins and trefoil factor family (TFF) peptides in the intrahepatic biliary system : physiological distribution and pathological significance. Prog Histochem Cytochem 42 : 61-110, 2007
PubMed
7) Sasaki M, Matsubara T, Kakuda Y et al : Immunostaining for polycomb group protein EZH2 and senescent marker p16INK4a may be useful to differentiate cholangiolocellular carcinoma from ductular reaction and bile duct adenoma. Am J Surg Pathol 38 : 364-369, 2014
PubMed
8) Sasaki M, Tsuneyama K, Ishikawa A et al : Intrahepatic cholangiocarcinoma in cirrhosis presents granulocyte and granulocyte-macrophage colony-stimulating factor. Hum Pathol 34 : 1337-1344, 2003
PubMed
9) Sasaki M, Sato Y, Nakanuma Y : Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Histopathology 70 : 423-434, 2017
PubMed
10) Sasaki M, Sato Y, Nakanuma Y : Cholangiolocellular carcinoma with "Ductal plate malformation" pattern may be characterized by ARID1A genetic alterations. Am J Surg Pathol 43 : 352-360, 2019
PubMed
11) Roskams T A, Theise N D, Balabaud C et al : Nomenclature of the finer branches of the biliary tree : canals, ductules, and ductular reactions in human livers. Hepatology 39 : 1739-45, 2004
PubMed
12) Nakanuma Y, Sasaki M, Terada T et al : Intrahepatic peribiliary glands of humans. II. Pathological spectrum. J Gastroenterol Hepatol 9 : 80-86, 1994
PubMed
P.116 掲載の参考文献
1) Tsui WM, Nakanuma Y : Biliary adenofibroma. in WHO Classification of Tumours Editrial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp248-249
 
2) Tsui WM, Loo KT, Chow LT et al : Biliary adenofibroma. A heretofore unrecognized benign biliary tumor of the liver. Am J Surg Pathol 17 : 186-192, 1993
PubMed
3) Tsutsui A, Bando Y, Sato Y et al : Biliary adenofibroma with ominous features of imminent malignant changes. Clin J Gastroenterol 7 : 441-448, 2014
PubMed
4) Nguyen NT, Harring TR, Holley L et al : Biliary adenofibroma with carcinoma in situ : a rare case report. Case Reports Hepatol 2012 : 793963, 2012
PubMed
5) Kaminsky P, Preiss J, Sasatomi E et al : Biliary adenofibroma : A rare hepatic lesion with malignant features. Hepatology 65 : 380-383, 2017
PubMed
6) Thai E, Dalla Valle R, Evaristi F et al : A case of biliary adenofibroma with malignant transformation. Pathol Res Pract 212 : 468-470, 2016
PubMed
7) Meguro S, Yamazaki S, Matsushima S et al : A case of primary hepatic so-called adenosarcoma with heterotopic ossification : possibly of biliary adenofibroma origin. Hum Pathol 73 : 108-113, 2018
PubMed
8) Thompson SM, Zendejas-Mummert B, Hartgers ML et al : Malignant transformation of biliary adenofibroma : a rare biliary cystic tumor. J Gastrointest Oncol 7 : E107-E112, 2016
PubMed
9) Varnholt H, Vauthey JN, Cin PD et al : Biliary adenofibroma : a rare neoplasm of bile duct origin with an indolent behavior. Am J Surg Pathol 27 : 693-698, 2003
 
10) Arnason T, Borger DR, Corless C et al : Biliary adenofibroma of the liver : morphology, tumor genetics, and outcomes in 6 cases. Am J Surg Pathol 41 : 499-505, 2017
PubMed
P.122 掲載の参考文献
1) Sempoux C, Kakar S, Kondo F et al : Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. in WHO Classification of Tumours Editrial Boad (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp260-262
 
2) Brunt E, Aishima S, Clavien PA et al : cHCC-CCA : Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 68 : 113-126, 2018
PubMed
3) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版補訂版. 金原出版, 2019
 
4) Steiner PE, Higginson J : Cholangiolocellular carcinoma of the liver. Cancer 12 : 753-759, 1959
PubMed
5) Robrechts C, De Vos R, Van den Heuvel M et al : Primary liver tumour of intermediate (hepatocyte-bile duct cell) phenotype : a progenitor cell tumour? Liver 18 : 288-293, 1998
PubMed
6) Kim H, Park C, Han KH et al : Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype. J Hepatol 40 : 298-304, 2004
PubMed
7) Theise ND, Nakashima O, Park YN et al : Combined hepatocellular-cholangiocarcinoma. in Bosman FT, Carneiro F, Hruban RH et al (eds), WHO Classification of Tumours of the Digestive System 4th ed. IARC, 2010, pp225-227
 
8) Akiba J, Nakashima O, Hattori S et al : Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol 37 : 496-505, 2013
 
9) 日本肝癌研究会追跡調査委員会 : 第20回 全国原発性肝癌追跡調査報告 (2008～2009). 肝臓 60 : 258-293, 2019
 
10) Sasaki M, Sato Y, Nakanuma Y : Mutational landscape of combined hepatocellular carcinoma and cholangiocarcinoma, and its clinicopathological significance. Histopathology 70 : 423-434, 2017
PubMed
11) Kusano H, Naito Y, Mihara Y et al : Distinctive clinicopathological features and KRAS and IDH1/2 mutation status of cholangiolocellular carcinoma. Hepatol Res 50 : 84-91, 2020
PubMed
12) Malvi D, de Biase D, Fittipaldi S et al : Immunomorphology and molecular biology of mixed primary liver cancers : is Nestin a marker of intermediate-cell carcinoma? Histopathology 76 : 265-274, 2020
PubMed
13) Xue R, Chen L, Zhang C et al : Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell 35 : 932-947, 2019
PubMed
14) Tschaharganeh DF, Xue W, Calvisi DF et al : p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 158 : 579-592, 2014
PubMed
P.126 掲載の参考文献
1) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版補訂版. 金原出版. 2019, pp46-49
 
2) Theise ND, Curado MP, Franceschi S et al : Hepatocellular carcinoma. in Bosman FT, Carnerio F, Hruban RH et al (eds), WHO Classification of Tumors of the Digestive System 4th ed. IARC, 2010, p196 & pp205-216
 
3) Sempox C, Kakar S, Kondo F et al : Combined hepatocellular-cholangiocarcinoma and undifferentiated primary liver carcinoma. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp260-262
 
4) Torbenson M, Zen Y, Yeh MM : AFIP Atlas of Tumor Pathology Series 4, Fascicle 27 Tumors of the Liver, American Registry of Pathology, 2018
 
5) Ishak KG, Goodman ZD, Stocker JT : AFIP Atlas of Tumor Pathology 3rd Series, Fascicle 31 Tumors of the Liver and Intrahepatic Bile Ducts. American Registry of Pathology, 2001
 
P.130 掲載の参考文献
1) Klismstra DS : Hepatic neuroendocrine neoplasms. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp263-264
 
2) Nomura Y, Nakashima O, Akiba J et al : Clinicopathological Features of Neoplasms with Neuroendocrine Differentiation Occurring in the Liver. J Clin Pathol 70 : 563-570, 2017
 
3) Torbenson M, Zen Y, Yeh MM : Neuroendocrine tumors/Carcinomas. in AFIP Atlas of Tumor Pathology Series 4, Fascicle 27 Tumors of the liver. American Registry of Pathology, 2018, pp375-379
 
P.133 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed.) : WHO Classification of Tumours 5th ed. Digestive System Tumors. IARC, 2019
 
2) Kwon HJ, Kim JW, Kim H et al : Combined hepatocellular carcinoma and neuroendocrine carcinoma with ectopic secretion of parathyroid hormone : A case report and review of the literature. J Pathol Transl Med 52, 232-237, 2018
PubMed
3) Okumura Y, Kohashi K, Wang H et al : Combined primary hepatic neuroendocrine carcinoma and hepatocellular carcinoma with aggressive biological behavior (adverse clinical course) : A case report. Pathol Res Pract 213, 1322-1326, 2017
PubMed
4) Treglia G, Castaldi P, Rindi G et al : Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours : a meta-analysis. Endocrine 42, 80-87, 2012
PubMed
5) Harada K, Sato Y, Ikeda H et al : Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organs. Virchows Arch 460, 281-289, 2012
PubMed
6) Zheng SL, Yip VS, Pedica F et al : Intrahepatic bile duct mixed adenoneuroendocrine carcinoma : a case report and review of the literature. Diagn Pathol 10, 204, 2015
PubMed
7) Nomura Y, Nakashima O, Akiba J et al : Clinicopathological features of neoplasms with neuroendocrine differentiation occurring in the liver. J Clin Pathol 70, 563-570, 2017
 
8) 原田憲一, 中沼安二 : 神経内分泌腫瘍. 肝・胆・膵 62, 163-169, 2011
Medical*Online
9) Lloyd RV, Douglas B, Young W : Atlas of nontumor pathology : endocrine diseases. in Ishak KG, Goodman ZD, Stocker JT (eds), AFIP Atlas of the Tomor Pathology 3rd Series, Fascicle 31 Tumors of the Liver and Intrahepatic Bile Ducts. American Registry of Pathology 2001, pp171-257
 
10) Baker E, Jacobs C, Martinie J et al : Mixed Hepatocellular carcinoma, neuroendocrine carcinoma of the liver. Am Surg 2016 ; 82, 1121-1125
 
P.138 掲載の参考文献
1) 奥平定之 : Focal nodular hyperplasia 23 切除例の臨床病理学的検討. 肝臓 34 : 621-629, 1993
 
2) Miura Y, Kondo K, Oikawa J et al : Contrast-enhanced ultrasonography using Levovist : Usefulness of diagnosis of small focal nodular hyperplasia lesions. J Med Ultrason 29 : 99-104, 2002
 
3) 近藤福雄, 副島友莉恵, 福里利夫 : 良性肝細胞性結節の病理診断 : 新WHO分類をふまえて. 肝臓 54 : 807-818, 2013
 
4) 中島収, 渡辺次郎, 田中将也他 : アルコール多飲者の肝過形成結節に関する臨床病理学的研究. 肝臓 37 : 704-713, 1996
 
5) 近藤福雄 : 肝癌の類似病変. 癌の臨床 47 : 933-943, 2001
Medical*Online
6) Kondo F : Benign nodular hepatocellular lesions caused by abnormal hepatic circulation : etiological analysis and introduction of a new concept. J Gastroenterol Hepatol 16 : 1319-1328, 2001
PubMed
7) 奥平雅彦 : 特発性門脈圧亢進症の肝臓病変, 特に肝内門脈血栓の存否とその意義についての検討小委員会報告. 二川俊二 (編) : 厚生省特定疾患門脈血行異常症調査研究班 平成6年度研究報告書, 1996, pp69-70
 
8) 近藤福雄 : 非硬変性門脈圧亢進症 (肝内血行異常) と肝内結節性病変について (第二報), 特に定型例と非定型例の問題解決のために. 日本門脈圧亢進症学会雑誌 5 : 247-256, 1999
 
9) Kumagai H, Masuda T, Oikawa H et al : Focal nodular hyperplasia of the liver : direct evidence of circulatory disturbances. J Gastroenterol Hepatol 15 : 1344-1347, 2000
PubMed
10) Wanless IR, Albrecht S, Bilbao J et al : Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain : a new syndrome. Mod Pathol 2 : 456-462, 1989
 
P.147 掲載の参考文献
1) Kanamori Y, Hashizume K, Kitano Y et al : Congenital extrahepatic portocaval shunt (Abernethy type 2), huge liver mass, and patent ductus arteriosus-a case report of its rare clinical presentation in a young girl. J Pediatr Surg 38 : E15, 2003
 
2) Wanless IR, Lentz JS, Roberts EA : Partial nodular transformation of liver in adult with persistent ductus venosus. Review with hypothesis on pathogenesis. Arch Pathol Lab Med 109 : 427-432, 1985
PubMed
3) 近藤福雄 : 良性非腫瘍性肝細胞過形成結節 (FNH類似病変). 病理と臨床 25 : 812-813, 2007
 
4) Kondo F, Koshima Y, Ebara M : Nodular lesions associated with abnormal liver circulation. Intervirology 47 : 277-287, 2004
PubMed
5) Kondo F : Benign nodular hepatocellular lesions caused by abnormal hepatic circulation : Etiological analysis and introduction of a new concept. J Gastroenterol Hepatol 16 : 1319-1328, 2001
PubMed
6) Fu R, Qiu T, Ling W et al : Nodular focal fat sparing of liver mimicking hepatocellular carcinoma in contrast-enhanced ultrasound. A case report. Medicine (Baltimore) 98 : e15431, 2019
PubMed
7) Delli Pizzi A, Mastrodicasa D, Sessa B et al : Multiple liver pseudotumors due to hepatic steatosis & fatty sparing : A non-invasive imaging approach. Eur J Radiol Open 6 : 56-59, 2019
PubMed
8) Sherlock S, Feldman CA, Moran B et al : Partial nodular transformation of the liver with portal hypertension. Am J Med 40 : 195-203, 1966
PubMed
9) Sherlock SA, Dooley J : Nodules and benign liver lesions. in Sherlock SA, Dooley J (eds), Diseases of the Liver and Biliary System 11th ed. Blackwell Science, 2002, pp527-535
 
10) Dhiman RK, Chawla Y, Vashishta RK et al : Non-cirrhotic portal fibrosis (idiopathic portal hypertension) : experience with 151 patients and a review of the literature. J Gastroenterol Hepatol 17 : 6-16, 2002
 
11) Terayama N, Terada T, Hoso M et al : Partial nodular transformation of the liver with portal thrombosis. A report of two autopsy cases. J Clin Gastroenterol 20 : 71-76, 1995
 
12) Wanless IR, Gryfe A : Nodular transformation of the liver in hereditary hemorrhagic telangiectasia. Arch Pathol Lab Med 110 : 331-335, 1986
PubMed
13) Isobe Y, Yamasaki T, Yokoyama Y et al : Hepatocellular carcinoma developing six and a half years after a diagnosis of idiopathic portal hypertension. J Gastroenterol 42 : 407-409, 2007
 
14) Okuda K, Obata H : Idiopathic portal hypertension (hepatoportal sclerosis). in Okuda K, Benhamon J-P (eds), Portal Hypertension. Clinical and Physiological Aspects. Springer-Verlag, 1991, pp271-287
 
15) 中島敏郎, 鹿毛政義 : 特発性門脈圧亢進症. 中島敏郎, 鹿毛政義 (編), 門脈圧亢進症の病理-肝内血管系の変化を中心に. 医学書院, 1996, pp65-75
 
16) Gridley G, Klippel JH, Hoover RN et al : Incidence of cancer among men with Felty syndrome. Ann Intern Med 120 : 35-39, 1994
PubMed
17) Wanless IR : Vascular disorders of the liver. in Odze RD, Goldblum JR, Crawford JM (eds), Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Saunders, 2004, pp885-907
 
18) Dachman AH, Ros PR, Goodman ZD et al : Nodular regenerative hyperplasia of the liver : clinical and radiologic observations. AJR Am J Roentgenol 148 : 717-722, 1987
PubMed
19) 近藤福雄 : 肝癌類似病変-診断へのアプローチ-病理形態学の立場から生検診断上の問題点. 肝胆膵 29 : 21-29, 1994
 
20) Naber AH, Van Haelst U, Yap SH : Nodular regenerative hyperplasia of the liver : an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 12 : 94-99, 1991
PubMed
21) Wanless IR : Micronodular transformation (nodular regenerative hyperplasia) of the liver : a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 11 : 787-797, 1990
 
22) Reynolds WJ, Wanless IR : Nodular regenerative hyperplasia of the liver in a patient with rheumatoid vasculitis : a morphometric study suggesting a role for hepatic arteries in the pathogenesis. J Rheumatol 11 : 838-842, 1984
 
23) Wanless IR, Godwin TA, Allen F et al : Nodular regenerative hyperplasia of the liver in hematologic disorders : A possible response to obliterative portal venopathy. A morphometric study of nine cases with a hypothesis on the pathogenesis. Medicine (Baltimore) 59 : 367-379, 1980
PubMed
24) Blendis LN, Parkinson MC, Shilkin KB et al : Nodular regenerative hyperplasia of the liver in Felty's syndrome. Q J Med 43 : 25-32, 1974
 
25) Kuramochi S, Tashiro Y, Torikata C et al : Systemic lupus erythematosus associated with multiple nodular hyperplasia of the liver. Acta Pathol Jpn 32 : 547-560, 1982
PubMed
26) Bloxham CA, Henderson DC, Hampson J et al : Nodular regenerative hyperplasia of the liver in Behcet's disease. Histopathology 20 : 452-454, 1992
PubMed
27) Solis Herruzo JA, Vidal JV, Colina F et al : Nodular regenerative hyperplasia of the liver associated with toxic oil syndrome : Report of five cases. Hepatology 6 : 687-693, 1986
PubMed
28) Lurie B, Novis B, Bank S et al : CRST syndrome and nodular transformation of the liver. A case report. Gastroenterology 64 : 457-461, 1973
PubMed
29) Lepelley M, Allouchery M, Long J et al : Nodular regenerative hyperplasia induced by trastuzumab emtansine : role of emtansine? Ann Hepatol 17 : 1067-1071, 2018
PubMed
30) Dumas K, Wilbur M, Dillon J et al : Paraneoplastic nodular regenerative hyperplasia of the liver associated with placental site trophoblastic tumor. Gynecol Oncol Rep 29 : 16-19, 2019
PubMed
31) Meijer B, Simsek M, Blokzijl H et al : Nodular regenerative hyperplasia rarely leads to liver transplantation : A 20-year cohort study in all Dutch liver transplant units. United Eur Gastroenterol J 5 : 658-667, 2017
 
32) Ibarrola C, Castellano VM, Colina F : Focal hyperplastic hepatocellular nodules in hepatic venous outflow obstruction : a clinicopathological study of four patients and 24 nodules. Histopathology 44 : 172-179, 2004
PubMed
33) Kim H, Nahm JH, Park YN : Budd-Chiari syndrome with multiple large regenerative nodules. Clin Mol Hepatol 21 : 89-94, 2015
PubMed
34) Schawkat K, Reiner CS : Diffuse liver disease : Cirrhosis, focal lesions in cirrhosis, and vascular liver disease. in Hodler J, Kubik-Huch GK, von Schulthess GK (eds), Diseases of the Abdomen and Pelvis 2018-2021. Diagnostic Imaging-IDKD Book, Springer 2018. Chapter 21
 
35) International Working Party : Terminology of nodular hepatocellular lesions. Hepatology 22 : 983-993, 1995
PubMed
36) Rapp JB, Bellah RD, Maya C et al : Giant hepatic regenerative nodules in Alagille syndrome. Pediatr Radiol 47 : 197-204, 2017
PubMed
37) Shrestha SM : Liver cirrhosis and hepatocellular carcinoma in hepatic vena cava disease, a liver disease caused by obstruction of inferior vena cava. Hepatol Int 33 : 392-402, 2009
 
38) Inada M, Kita K, Kondo F et al : Large regenerative nodule perfused by the portal vein. J Gastroenterol Hepatol 20 : 1794-1798, 2005
PubMed
39) Anthony PP, Vogel CL, Barker LF : Liver cell dysplasia. A premalignant condition. J Clin Pathol 26 : 217-223, 1973
PubMed
40) Watanabe S, Okita K, Harada T et al : Morphologic studies of the liver cell dysplasia. Cancer 51 : 2197-2205, 1983
PubMed
41) Baecker A, Liu X, Vecchia CL et al : Worldwide incident hepatocellular carcinoma cases attributable to major risk factors. Eur J Cancer Prev 27 : 205-212, 2018
 
42) Matsushita H, Takaki A : Alcohol and hepatocellular carcinoma. BMJ Open Gastroenterol 6 : e000260, 2019
PubMed
43) Moon JH, Ahn CM, Chung HS et al : A case of hypervascular hyperplastic nodules in a patient with alcoholic liver cirrhosis. Yonsei Med J 47 : 881-886, 2006
 
44) Kim SR, Kondo F, Otono Y et al : Serum amyloid A and Creactive protein positive nodule in alcoholic liver cirrhosis, hard to make definite diagnosis. Hepatol Res 44 : 584-590, 2014
 
45) Sasaki M, Nakanuma Y : Serum amyloid A positive hepatocellular neoplasm : a new type of tumor arising in patients with advanced alcoholic disease. Dig Dis 33 : 648-654, 2015
PubMed
46) Kondo F : Focal nodular hyperplasia-like lesions in heavy drinkers. Internal Med 48 : 1117-1123, 2009
 
47) Takeyama J, Ando R, Sato T et al : Focal nodular hyperplasia-like lesion of the liver in a child previously treated for nephroblastoma. Pathol Int 58 : 606-608, 2008
 
48) Kim SR, Imoto S, Ikawa H et al : Focal nodular hyperplasia-like lesion with venous washout in alcoholic liver cirrhosis. Intern Med 47 : 1899-1903, 2008
PubMed
49) Takahashi S, Miyanishi K, Takada K et al : Case report of a focal nodular hyperplasia-like nodule present in cirrhotic liver. Hepatol Res 38 : 521-528, 2008
PubMed
50) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版. 金原出版, 2015, p45
 
51) International Consensus Group for Hepatocellular Neoplasia : International diagnosis of early hepatocellular carcinoma : a report of the international consensus group for hepatocellular neoplasia. Hepatology 49 : 658-664, 2009
 
P.156 掲載の参考文献
1) Torbenson MS : Hamartomas and malformations of the liver. Semin Diagnos Path 36 : 39-47, 2019
 
2) Goodman ZD, Terracciano LM : Tumours and tumour-like lesions of the liver. in Burt AD, Ferrell LD, Hubscher SG (eds) MacSween's Pathology of the Liver 7th ed. Elsevier, 2018, pp761-851
 
3) Torbenson M, Zen Y, Yeh MM : AFIP Atlas of Tumor Pathology Series 4, Fascicle 27 Tumors of the Liver. American Registry of Pathology, 2018, pp189-195
 
4) Melnick PJ : Polycystic liver : analysis of seventy cases. AMA Arch Pathol 59 : 162-172, 1955
PubMed
5) Xu AM, Xian ZH, Zhang SH et al : Intrahepatic cholangiocarcinoma arising in multiple bile duct hamartomas : report of two cases and review of the literature. Eur J Gastroenterol Hepatol 21 : 580-584, 2009
PubMed
6) Yoshida S, Kurokohchi K, Ueno T et al : Hepatic von Meyenburg complex : a trigger of severe portal hypertension. Liver Int 29 : 614-615, 2009
 
7) Hornick JL, Lauwers GY, Odze RD : Immunohistochemistry can help distinguish metastatic pancreatic adenocarcinomas from bile duct adenomas and hamartomas of the liver. Am J Surg Pathol 29 : 381-389, 2005
PubMed
8) Tan G, Yilmaz A, De Young BR et al : Immunohistochemical analysis of biliary tract lesions. Appl Immunohistochem Mol Morphol 12 : 193-197, 2004
PubMed
9) Chu AS, Friedman JR : A role for microRNA in cystic liver and kidney diseases. J Clin Invest 118 : 3585-3587, 2008
PubMed
10) Kondo F : Benign nodular hepatocellular lesions caused by abnormal hepatic circulation : etiological analysis and introduction of a new concept. J Gastroenterol Hepatol 16 : 1319-1328, 2001
PubMed
11) Pujals A, Bioulac-Sage P, Castain C et al : BRAF V600E mutational status in bile duct adenomas and hamartomas. Histopathology 67 : 562-567, 2015
PubMed
12) Bhathal PS, Hughes NR, Goodman ZD : The so-called bile duct adenoma is a peribiliary gland hamartoma. Am J Surg Pathol 20 : 858-864, 1996
PubMed
13) Wei J, Zhang D, Yang J et al : Intrahepatic bile duct adenoma (peribiliary gland hamartoma) : a case report and review of literature. Int J Clin Exp Pathol 8 : 5908-5913, 2015
 
14) WHO Classification of the Tumours Editorial Board (ed.) : WHO Classification of the Tumours 5th ed. Digestive System Tumours. IARC, 2019
 
15) Siddiqui MA, McKenna BJ : Hepatic mesenchymal hamartoma : a short review. Arch Pathol Lab Med 130 : 1567-1569, 2006
 
16) Apellaniz-Ruiz M, Segni M, Kettwig M et al : Mesenchymal hamartoma of the liver and DICER1 syndrome. N Engl J Med 380 : 1834-1842, 2019
PubMed
17) Zen Y, Terahata S, Miyayama S et al : Multicystic biliary hamartoma : a hitherto undescribed lesion. Hum Pathol 37 : 339-344, 2006
PubMed
18) Beard RE, Yee EU, Mortele KJ : Multicystic biliary hamartoma : A report of a rare entity and a review of the literature. Int J Surg Case Rep 5 : 919-23, 2014
 
19) Tominaga T, Abo T, Kinoshita N et al : A variant of multicystic biliary hamartoma presenting as an intrahepatic cystic neoplasm. Clin J Gastroenterol 8 : 162-166, 2015
PubMed
20) Kobayashi A, Takahashi S, Hasebe T et al : Solitary bile duct hamartoma of the liver. Scand J Gastroenterol 40 : 1378-1381, 2005
PubMed
P.162 掲載の参考文献
1) Rosa B, Moutinho-Ribeiro P, Pereira JM et al : Ghost tumor : An inflammatory pseudotumor of the liver. Gastroenterol Hepatol 8 : 630-633, 2012
PubMed
2) Zen Y, Fujii T, Sato Y et al : Pathological classification of hepatic inflammatory pseudotumor with respect to IgG4-related disease. Mod Pathol 20 : 884-894, 2007
PubMed
3) Park JY, Choi MS, Lim YS et al : Clinical features, image findings, and prognosis of inflammatory pseudotumor of the liver : a multicenter experience of 45 cases. Gut Liver 8 : 58-63, 2014
PubMed
4) Nakanuma Y, Tsuneyama K, Masuda S et al : Hepatic inflammatory pseudotumor associated with chronic cholangitis : report of three cases. Hum Pathol 25 : 86-91, 1994
PubMed
5) Nigam N, Rajani SS, Rastogi A et al : Inflammatory pseudotumors of the liver : Importance of a multimodal approach with the insistance of needle biopsy. J Lab Physicians 11 : 361-368, 2019
PubMed
6) Zen Y, Harada K, Sasaki M et al : IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis : do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol 28 : 1193-1203, 2004
PubMed
7) Kamisawa T, Nakazawa T, Tazuma S et al : Clinical practice guidelines for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci 26 : 9-42, 2019
PubMed
8) Yamamoto H, Yamaguchi H, Aishima S et al : Inflammatory myofibroblastic tumor versus IgG4-related sclerosing disease and inflammatory pseudotumor : a comparative clinicopathologic study. Am J Surg Pathol 33 : 1330-1340, 2009
PubMed
9) Seitter S, Goodman ZD, Friedman TM et al : Intrahepatic reactive lymphoid hyperplasia : a case report and review of the literature. Case Rep Surg 9264251, 2018
PubMed
10) Li XQ, Cheuk W, Lam PW et al : Inflammatory pseudotumor-like follicular dendritic cell tumor of liver and spleen : granulomatous and eosinophil-rich variants mimicking inflammatory or infective lesions. Am J Surg Pathol 38 : 646-653, 2014
PubMed
P.168 掲載の参考文献
1) Kobayashi S, Gabata T, Matsui O : Radiologic manifestation of hepatic pseudolesion and pseudotumor in the third inflow area. Imaging in Medicine 2 : 519-528, 2010
 
2) Kobayashi S, Nakanuma Y, Matsui O : Intrahepatic peribiliary vascular plexus in various hepatobiliary diseases : a histological survey. Hum Pathol 25 : 940-946, 1994
PubMed
3) Yu JS, Kim KW, Jeong MG et al : Nontumorous hepatic arterial-portal venous shunts : MR imaging findings. Radiology 217 : 750-756, 2000
PubMed
4) Mori K, Yoshioka H, Itai Y et al : Arterioportal shunts in cirrhotic patients : evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide. AJR Am J Roentgenol 175 : 1659-1764, 2000
PubMed
5) Motosugi U, Ichikawa T, Sou H et al : Distinguishing hypervascular pseudolesions of the liver from hypervascular hepatocellular carcinomas with gadoxetic acid-enhanced MR imaging. Radiology 256 : 151-158, 2010
PubMed
6) Yoshimitsu K, Honda H, Kuroiwa T et al : Unusual hemodynamics and pseudolesions of the noncirrhotic liver at CT. Radiographics S81-96, 2001
PubMed
7) Matsui O, Takahashi S, Kadoya M et al : Pseudolesion in segment IV of the liver at CT during arterial portography : correlation with aberrant gastric venous drainage. Radiology 193 : 31-35, 1994
PubMed
8) Hashimoto M, Heianna J, Tate E et al : Small veins entering the liver. Eur Radiol 12 : 2000-2005, 2002
PubMed
9) Kawamori Y, Matsui O, Takahashi S et al : Focal hepatic fatty infiltration in the posterior edge of the medial segment associated with aberrant gastric venous drainage : CT, US, and MR findings. J Comput Assist Tomogr 20 : 356-359, 1996
 
10) Matsui O, Kadoya M, Takahashi S et al : Focal sparing of segment IV in fatty livers shown by sonography and CT : correlation with aberrant gastric venous drainage. AJR Am J Roentgenol 164 : 1137-1140, 1995
PubMed
11) Matsui O, Kadoya M, Yoshikawa J et al : Aberrant gastric venous drainage in cirrhotic livers : imaging findings in focal areas of liver parenchyma. Radiology 197 : 345-349, 1995
PubMed
12) Hoshiba K, Demachi H, Miyata S et al : Fatty infiltration of the liver distal to a metastatic liver tumor. Abdom Imaging 22 : 496-498, 1997
PubMed
13) Yoshimitsu K, Irie H, Kakihara D et al : Postgastrectomy development or accentuation of focal fatty change in segment IV of the liver : correlation with the presence of aberrant venous branches of the parabiliary venous plexus. J Clin Gastroenterol 41 : 507-512, 2007
PubMed
P.174 掲載の参考文献
1) Miettinen M, Fletcher CDM, Kindblom LG et al : Mesenchymal tumor of the liver. in Bosman FT, Carneiro F, Hruban RH (eds), WHO Classification of Tumours of the Digestive System 4th ed. IARC 2010, pp243-244
 
2) Torbenson M, Zen Y, Yeh MM (eds) : AFIP Atlas of the Tumor Pathology Series 4, Fascicle 27 Tumors of the liver. American Registry of Pathology, 2018, pp2879-3284
 
3) 松井修, 角谷真澄, 小坂一斗他 : 肝の画像診断 画像の成り立ちと病理・病態 第2版 医学書院 2019, pp207-209, 256-258
 
4) 山下康行 : 肝胆膵の画像診断A Key to Hepatobiliary and Pancreatic Imaging-CT, MRIを中心に-画像診断別冊 (KEY BOOKシリーズ). 学研メディカル秀潤社, 2019, pp154-159, 162-163
 
5) Miyamoto S, Oshita A, Daimaru Y et al : Hepatic sclerosed hemangioma : a case report and review of the literature. BMC Surgery 15 : 45, 2015
PubMed
6) Yanoff M, Rawson AJ : Peliosis hepatis. An anatomic study with demonstration of two varieties. Arch Pathol 77 : 159-165, 1964
PubMed
7) Tsokos M, Erbersdobler A : Pathology of peliosis. Forensic Sci Int 149 : 25-33, 2005
PubMed
8) Ferrell LD, Kakar S, Terracciano LM el al : Peliosis hepa tis. in Burt AD, Ferrell LD, Hubscher SG (eds), MacSween's Pathology of the Liver 7th ed. 2017, p646
 
9) Hayward SR, Lucas CE, Ledgerwood AM : Recurrent spontaneous intrahepatic hemorrhage from peliosis hepatis. Arch Surg 126 : 782-783, 1991
PubMed
10) Wold LE, Ludwig J : Peliosis hepatis : two morphologic variants? Human Pathol 12 : 388-389, 1981
 
11) Crocetti D, Palmieri A, Pedulla G et al : Peliosis hepatis : Personal experience and literature review. World J Gastroenterol 21 : 13188-13194, 2015
PubMed
P.180 掲載の参考文献
1) Lazar DC, Avram MF, Romosan I et al : Malignant hepatic vascular tumors in adults : Characteristics, diagnostic difficulties and current management. World J Clin Oncol 10 : 110-135, 2019
 
2) Zhu YP, Chen YM, Matro E et al : Primary hepatic angiosarcoma : A report of two cases and literature review. World J Gastroenterol 21 : 6088-6096, 2015
PubMed
3) Lerut J, Iesari S : Vascular tumours of the liver : a particular story. Transl Gastroenterol Hepatol 3 : 62, 2018
PubMed
4) Yuan WH, Li AF, Hsu HC et al : Initial clinical radiological findings and staging to predict prognosis of primary hepatic angiosarcoma : a retrospective analysis. PLoS One 14 (11), e0225043, 2019
PubMed
5) Gill RM, Buelow B, Mather C et al : Hepatic small vessel neoplasm, a rare infiltrative vascular neoplasm of uncertain malignant potential. Hum Pathol 54 : 143-151, 2016
PubMed
6) Choi HH, Manning MA, Mehrotra AK et al : Primary hepatic neoplasms of vascular origin : key imaging features and differential diagnoses with radiology-pathology correlation. AJR Am JRoentgenol 209 : w350-359, 2017
PubMed
7) Yasir S, Torbenson MS : Angiosarcoma of the Liver : Clinicopathologic features and morphologic patterns. Am J Surg Pathol 43 : 581-590, 2019
PubMed
8) Walcott-Sapp S, Tang E, Kakar S et al : Resection of the largest reported hepatic small vessel neoplasm. Hum Pathol 78 : 159-162, 2018
PubMed
P.187 掲載の参考文献
1) Ishak KG : Mesenchymal tumors of the liver. in Okuda K, Peters RL (eds), Hepatocellular Carcinoma. Wiley Medical, 1976, pp247-307.
 
2) Nonomura A, Enomoto Y, Takeda M et al : Angiomyolipoma of the liver : a reappraisal of morphological features and delineation of new characteristic histological features from the clinicopathological findings of 55 tumours in 47 patients. Histopathol 61 : 863-880, 2012
 
3) Dalle I, Sciot R, de Vos R et al : Malignant angiomyolipoma of the liver : a hitherto unreported variant. Histopathol 36 : 443-450, 2000.
 
4) Nonomura A, Enomoto Y, Takeda M et al : Invasive growth of hepatic angiomyolipoma ; a hitherto unrecognized ominous histological feature. Histopathol 48 : 831-835, 2006.
 
5) Siroky BJ, Yin H, Dixon BP et al : Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy. Am J Physiol Renal Physiol 307 : f560-f570, 2014.
PubMed
6) Jimbo N, Nishigami T, Noguchi M et al : Hepatic angiomyolipomas may overexpress TFE3, but have no relevant genetic alterations. Hum Pathol 61 : 41-48, 2017.
PubMed
P.191 掲載の参考文献
1) Weiss SW, Enzinger FM : Epithelioid hemangioendothelioma : A vascular tumor often mistaken for a carcinoma. Cancer 50 : 970-981, 1982
PubMed
2) Makhlouf HR, Ishak KG, Goodman ZD : Epithelioid hemangioendothelioma of the liver : a clinicopathologic study of 137 cases. Cancer 85 : 562-582, 1999
PubMed
3) Noh OK, Kim SS, Yang MJ et al : Treatment and prognosis of hepatic epithelioid hemangioendothelioma based on SEER data analysis from 1973 to 2014. Hepatobiliary Pancreat Dis Int 19 : 29-35, 2019
 
4) Woodall CE, Scoggins CR, Lewis AM et al : Hepatic malignant epithelioid hemangioendothelioma : a case report and review of the literature. Am Surg 74 : 64-68, 2008
PubMed
5) Gill R, O'Donnell RJ, Horvai A : Utility of immunohistochemistry for endothelial markers in distinguishing epithelioid hemangioendothelioma from carcinoma metastatic to bone. Arch Pathol Lab Med 133 : 967-972, 2009
 
6) Shibuya R, Matsuyama A, Shiba E et al : CAMTA1 is a useful immunohistochemical marker for diagnosing epithelioid haemangioendothelioma. Histopathology 67 : 827-835, 2015
PubMed
7) Doyle LA, Fletcher CD, Hornick JL : Nuclear expression of CAMTA1 distinguishes epithelioid hemangioendothelioma from histologic mimics. Am J Surg Pathol 40 : 94-102, 2016
PubMed
8) Mendlick MR, Nelson M, Pickering D et al : Translocation t (1 ; 3) (p36.3 ; q25) is a nonrandom aberration in epithelioid hemangioendothelioma. Am J Surg Pathol 25 : 684-687, 2001
PubMed
9) Errani C, Zhang L, Sung YS et al : A novel WWTR1-CAMTA1 gene fusion is a consistent abnormality in epithelioid hemangioendothelioma of different anatomic sites. Genes Chromosomes Cancer 50 : 644-653, 2011
PubMed
10) Antonescu CR, Le Loarer F, Mosquera JM et al : Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 52 : 775-784, 2013
PubMed
11) Patel NR, Salim AA, Sayeed H et al : Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1-CAMTA1 fusion variants. Histopathology 67 : 699-708, 2015
PubMed
P.198 掲載の参考文献
1) Noronha V, Shafi NQ, Obando JA et al : Primary non-Hodgkin's lymphoma of the liver. Crit Rev Oncol Hematol 53 : 199-207, 2005
PubMed
2) Loddenkemper C, Longerich T, Hummel M et al : Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification. Virchows Arch 450 : 493-502, 2007
 
3) El-Fattah MA : Non-Hodgkin lymphoma of the liver : a US population-based analysis. J Clin Transl Hepatol 5 : 83-91, 2017
PubMed
4) Eom DW, Huh JR, Kang YK et al : Clinicopathological features of eight Korean cases of primary hepatic lymphoma. Pathol Int 54 : 830-836, 2004
PubMed
5) Murakami J, Shimizu Y : Hepatic manifestations in hematological disorders. Int J Hepatol. 2013 : 484903, 2013
PubMed
6) Santos ES, Raez LE, Salvatierra J et al : Primary hepatic non-Hodgkin's lymphomas : case report and review of the literature. Am J Gastroenterol 98 : 2789-2793, 2003
 
7) Anderson LA, Gadalla S, Morton LM et al : Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies. Int J Cancer 125 : 398-405, 2009
PubMed
8) Rizzi EB, Schinina V, Cristofaro M et al : Non-hodgkin's lymphoma of the liver in patients with AIDS : sonographic, CT, and MRI findings. J Clin Ultrasound 29 : 125-129, 2001
PubMed
9) Sharifi S, Murphy M, Loda M et al : Nodular lymphoid lesion of the liver : an immune-mediated disorder mimicking low-grade malignant lymphoma. Am J Surg Pathol 23 : 302-308, 1999
PubMed
10) Inoue M, Tanemura M, Yuba T et al : A case of hepatic pseudolymphoma in a patient with primary biliary cirrhosis. Clin Case Rep 7 : 1863-1869, 2019
 
11) Sato S, Masuda T, Oikawa H et al : Primary hepatic lymphoma associated with primary biliar y cirrhosis. Am J Gastroenterol 94 : 1669-1673, 1999
 
P.205 掲載の参考文献
1) Stocker JT, Ishak KG : Undifferentiated (embryonal) sarcoma of the liver : report of 31 cases. Cancer 42 : 336-348, 1978
PubMed
2) Hormick JL, et al : Embryonal sarcoma of the liver. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp497-498
 
3) Ferrell LD, Kakar S, Terracciano LM et al : Tumours and tumor-like lesions of the liver. in Burt AD, Hubscher SG, Ferrell LD (eds), MacSween's Pathology of the Liver 7th ed. Elsevier, 2018, pp851-852
 
4) Torbenson M, Zen Y, Yeh MM : Mesenchymal tumors and tumor-like lesions. in AFIP Atlas of Tumor Pathology Series 4, Fascicle 27 Tumor of the Liver. American Registry of Pathology, 2018, pp317-329
 
5) Bisogno G, Pilz T, Perilongo G et al : Undifferentiated sarcoma of the liver in childhood : a curable disease. Cancer 94 : 252-257, 2002
PubMed
6) 野坂俊介, 宮坂実木子, 鹿島恭子他 : 特集稀な肝悪性腫瘍-画像と病理, 小児肝悪性腫瘍. 消化器画像 5 : 589-599, 2003
 
7) Buetow PC, Buck JL, Pantongrag-Brown L et al : Undifferentiated (embryonal) sarcoma of the liver : pathologic basis of imaging findings in 28 cases. Radiology 203 : 779-783, 1997
PubMed
8) 渋谷均, 高島健, 佐々木賢一他 : 原発性肝平滑筋肉腫の1例. 日臨外会誌 63 : 3017-3023, 2002.
 
9) 佐藤宗勝, 安田是和 : 肝原発平滑筋肉腫の1症例. 肝胆膵 47 : 885-891, 2003
Medical*Online
10) Fritchie KJ, Hornick JL, Rossi S : Solitary fibrous tumor. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019, pp448-449
 
11) Kandpal H, Sharma R, Gupta SD et al : Solitary fibrous tumour of the liver : a rare imaging diagnosis using MRI and diffusion-weighted imaging. Br J Radiol 81 : e282-286, 2008
PubMed
12) Zampieri N, Camoglio F, Corroppolo M et al : Botryoid rhabdomyosarcoma of the biliary tract in children : a unique case report. Eur J Cancer Care (Engl) 15 : 463-466, 2006
PubMed
13) Nemade B, Talapatra K, Shet T et al : Embryonal rhabdomyosarcoma of the biliary tree mimicking a choledochal cyst. J Cancer Res Ther 3 : 40-42, 2007
PubMed
14) Wada Y, Jimi A, Nakashima O et al : Schwannoma of the liver : report of two surgical cases. Pathol Int 48 : 611-617, 1998
PubMed
15) 今里光伸, 東野健, 加納寿之他 : 肝平滑筋腫の1例. 日外会誌 106 : 725-729, 2005
 
16) Watanabe J, Nakashima O, Noguchi K et al : Imaging and pathologic findings of pseudolipoma in the liver. Hepatol Res 12 : 225-232, 1998
 
17) Li YR, Akbari E, Tretiakova MS et al : Primary hepatic malignant fibrous histiocytoma : clinicopathologic characteristics and prognostic value of ezrin expression. Am J Surg Pathol 32 : 1144-1158, 2008
PubMed
18) Rosai J, Sobin LH : Malignant mesenchymal tumors. in Ishak KG, Goodman ZD, Stocker JT (eds). AFIP Atlas of Tumor Pathology 3rd Series, Fascicle 31 Tumor of the Liver and Intrahepatic Bile Ducts. American Registry of Pathology, 2001, pp281-330
 
19) Morikawa Y, Ishihara Y, Matsuura N et al : Malignant schwannoma of the liver. Dig Dis Sci 40 : 1279-1282, 1995
PubMed
20) Kim JL, Woo JY, Lee MJ et al : Imaging findings of primary well-differentiated liposarcoma of the liver : a case report. Acta Radiol 48 : 1061-1065, 2007
PubMed
P.212 掲載の参考文献
1) Yan BC, Gong C, Song J et al : Arginase-1 : a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol 34 : 1147-1154, 2010
PubMed
2) Fan Z, van de Rijn M, Montgomery K et al : Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma : 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol 16 : 137-144, 2003
 
3) Krings G, Ramachandran R, Jain D et al : Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma. Mod Pathol 26 : 782-791, 2013
 
4) Zynger DL, Dimov ND, Luan C et al : Glypican 3 : a novel marker in testicular germ cell tumors. Am J Surg Pathol 30 : 1570-1575, 2006
PubMed
5) Ferrone CR, Ting DT, Shahid M et al : The ability to diagnose intrahepatic cholangiocarcinoma definitively using novel branched DNA-enhanced albumin RNA in situ hybridization technology. Ann Surg Oncol 23 : 290-296, 2016
PubMed
6) Rullier A, Le Bail B, Fawaz R et al : Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol 24 : 870-876, 2000
PubMed
7) Demarez C, Hubert C, Sempoux C et al : Expression of molecular differentiation markers does not correlate with histological differentiation grade in intrahepatic cholangiocarcinoma. PLoS One 11 : e0157140, 2016
 
8) Werling RW, Yaziji H, Bacchi CE et al : CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin : an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol 27 : 303-310, 2003
PubMed
9) Shigematsu Y, Inamura K, Mise Y et al : CDX2 expression is concordant between primary colorectal cancer lesions and corresponding liver metastases independent of chemotherapy : a single-center retrospective study in Japan. Oncotarget 9 : 17056-17065, 2018
PubMed
10) Magnusson K, de Wit M, Brennan DJ et al : SATB2 in combination with cytokeratin 20 identifies over 95 % of all colorectal carcinomas. Am J Surg Pathol 35 : 937-948, 2011
PubMed
11) Gurel B, Ali TZ, Montgomery EA et al : NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 34 : 1097-1105, 2010
PubMed
12) Tong GX, Yu WM, Beaubier NT et al : Expression of PAX8 in normal and neoplastic renal tissues : an immunohistochemical study. Mod Pathol 22 : 1218-1227, 2009
PubMed
13) Tian W, Guner G, Miyamoto H et al : Utility of uroplakin II expression as a marker of urothelial carcinoma. Hum Pathol 46 : 58-64, 2015
PubMed
14) Rees M, Tekkis PP, Welsh FK et al : Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer : a multifactorial model of 929 patients. Ann Surg 247 : 125-135, 2008
PubMed
15) Knijn N, de Ridder JA, Punt CJ et al : Histopathological evaluation of resected colorectal cancer liver metastases : what should be done? Histopathology 63 : 149-156, 2013
PubMed
16) Sasaki A, Aramaki M, Kawano K et al : Prognostic significance of intrahepatic lymphatic invasion in patients with hepatic resection due to metastases from colorectal carcinoma. Cancer 95 : 105-111, 2002
PubMed
17) Gomez D, Zaitoun AM, De Rosa A et al : Critical review of the prognostic significance of pathological variables in patients undergoing resection for colorectal liver metastases. HPB (Oxford) 16 : 836-844, 2014
PubMed
18) Kokudo N, Miki Y, Sugai S et al : Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma : minimum surgical margins for successful resection. Arch Surg 137 : 833-840, 2002
PubMed
19) Rubbia-Brandt L, Giostra E, Brezault C et al : Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18 : 299-304, 2007
PubMed
20) Blazer DG, 3rd, Kishi Y, Maru DM et al : Pathologic response to preoperative chemotherapy : a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26 : 5344-5351, 2008
PubMed
21) Chang HH, Leeper WR, Chan G et al : Infarct-like necrosis : a distinct form of necrosis seen in colorectal carcinoma liver metastases treated with perioperative chemotherapy. Am J Surg Pathol 36 : 570-576, 2012
PubMed
22) Rubbia-Brandt L, Lauwers GY, Wang H et al : Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis. Histopathology 56 : 430-439, 2010
PubMed
23) Overman MJ, Maru DM, Charnsangavej C et al : Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28 : 2549-2555, 2010
PubMed
24) Overman MJ, Ferrarotto R, Raghav K et al : The addition of bevacizumab to oxaliplatin-based chemotherapy : impact upon hepatic sinusoidal injury and thrombocytopenia. J Natl Cancer Inst 110 : 888-894, 2018
PubMed
25) Vauthey JN, Pawlik TM, Ribero D et al : Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 : 2065-2072, 2006
 

第3部 鑑別ポイント

P.224 掲載の参考文献
1) Eguchi A, Nakashima O, Okudaira S et al : Adenomatous hyperplasia in the vicinity of small hepatocellular carcinoma. Hepatology 15 : 843-848, 1992
PubMed
2) International Working Party : Terminology of nodular hepatocellular lesion. Hepatology 22 : 983-993, 1995
PubMed
3) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第5版補訂版. 金原出版, 2009
 
4) Miyaaki H, Fujimoto M, Kurogi M et al : Pathological study on small nodular lesions in hepatitis C virus-related cirrhosis. Oncol Rep 14 : 1469-1474, 2005
 
5) Park YN, Yang CP, Fernandez GJ et al : Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. Am J Surg Pathol 22 : 656-662, 1998
PubMed
6) Roncalli M, Roz E, Coggi G et al : The vascular profile of regenerative and dysplastic nodules of the cirrhotic liver : Implications for diagnosis and classification. Hepatology 30 : 1174-1178, 1999
PubMed
7) International Consensus Group for Hepatocellular Neoplasia : Pathologic diagnosis of early hepatocellular carcinoma : a report of the international consensus group for hepatocellular neoplasia. Hepatology 49 : 658-664, 2009
 
8) Tommaso LD, Franchi G, Park YN et al : Diagnostic value of HSP 70, Glypican 3, and Glutamine Synthetase in hepatocellular nodules in cirrhosis. Hepatology 45 : 725-734, 2007
 
9) WHO Classification of Tumours Editorial Board (ed.) : WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019
 
10) 吉川淳, 松井修 : 限局性脂肪肝. 消化器画像 3 : 71-74, 2001
 
11) Kojiro M, Okudaira S, Nakashima O : Clinicopathologic characteristics of focal nodular hyperplasia (FNH) of the liver. J Hep Bil Pancr Surg 3 : 106-110, 1996
 
12) Nakashima O, Kurogi M, Yamaguchi R et al : Unique hypervascular nodules in alcoholic liver cirrhosis : identical to focal nodular hyperplasia-like nodules? J Hepatol 41 : 992-998, 2004
PubMed
13) Sasaki M, Yoneda N, Sawai Y et al : Clinicopathological characteristics of serum amyloid A-positive hepatocellular neoplasm/nodules arising in alcoholic cirrhosis. Histopathology 66 : 836-845, 2015
PubMed
14) Yan Z, Grenert JP, Joseph NM et al : Hepatic angiomyolipoma : mutation analysis and immunohistochemical pitfalls in diagnosis. Histopathology 73 : 101-108, 2018
PubMed
P.229 掲載の参考文献
1) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版補訂版. 金原出版, 2019, pp42-56
 
2) Sakamoto M, Hirohashi S, Tsuda H et al : Multicentric independent development of hepatocellular carcinoma revealed by analysis of hepatitis B virus integration pattern. Am J Surg Pathol 13 : 1064-1067, 1989
PubMed
3) Sakamoto M, Effendi K, Masugi Y. Molecular diagnosis of multistage hepatocarcinogenesis. Jpn J Clin Oncol 40 : 891-896, 2010
PubMed
4) Tsuda H, Hirohashi S, Shimosato Y et al : Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma. Gastroenterology 95 : 1664-1666, 1998
 
5) Tsuda H, Oda T, Sakamoto M et al : Different pattern of chromosomal allele loss in multiple hepatocellular carcinoma as evidence of their multifocal origin. Cancer Res 52 : 1504-1509, 1992
PubMed
6) Oikawa T, Ojima H, Yamasaki S et al : Multistep and multicentric development of hepatocellular carcinoma : histological analysis of 980 resected nodules. J Hepatol 42 : 225-229, 2005
PubMed
7) Torbenson MS, Ng IOL, Park YN et al : Hepatocellular carcinoma. in WHO Classification of Tumours Editorial Board (ed.), WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC 2019, pp229-239
 
8) Shimada M, Takenaka K, Taguchi K et al : Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma. Ann Surg 227 : 80-85, 1998
PubMed
9) Okusaka T, Okada S, Nose H et al : The prognosis of patients with hepatocellular carcinoma of multicentric origin. Hepatogastroenterology 43 : 919-925, 1996
PubMed
P.236 掲載の参考文献
1) 中沼安二, 全陽, 板津慶太 : 胆管内乳頭状腫瘍intraductal papillary neoplasm of bile duct (IPNB) -新しい疾患概念の提唱とその病理学的スペクトラム. 胆道 21 : 45-54, 2007
Medical*Online
2) Kozaka K, Sasaki S, Fujii T et al : A subgroup of intrahepatic cholangiocarcinoma with an infiltrating replacement growth pattern and a resemblance to reactive proliferating bile ductules : 'bile ductular carcinoma'. Histopathology 51 : 390-400, 2007
 
3) Kobayashi M, Ikeda K, Saitoh S et al : Incidence of primary cholangiocellular carcinoma of the liver in japanese patients with hepatitis C virus-related cirrhosis. Cancer 88 : 2471-2477, 2000
PubMed
4) Fujii T, Zen Y, Harada K et al : Participation of liver cancer stem/progenitor cells in tumorigenesis of scirrhous hepatocellular carcinoma-human and cell culture study. Hum Pathol 39 : 1185-1196, 2008
PubMed
5) Konopke R, Distler M, Ludwig S et al : Location of liver metastases reflects the site of the primary colorectal carcinoma. Scand J Gastroenterol 43 : 192-195, 2008
PubMed
6) Zen Y, Sasaki M, Fujii T et al : Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct-an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol 44 : 350-358, 2006
PubMed
7) Ishikawa A, Sasaki M, Ohira S, et al : Aberrant expression of CDX2 is closely related to the intestinal metaplasia and MUC2 expression in intraductal papillary neoplasm of the liver in hepatolithiasis. Lab Invest 84 : 629-638, 2004
 
8) Riopel MA, Klimstra DS, Godellas CV et al : Intrabiliary growth of metastatic colonic adenocarcinoma : a pattern of intrahepatic spread easily confused with primary neoplasia of the biliary tract. Am J Surg Pathol 21 : 1030-1036, 1997
PubMed
9) Harada K, Kono N, Tsuneyama K et al : Cell-kinetic study of proliferating bile ductules in various hepatobiliary diseases. Liver 18 : 277-284, 1998
PubMed
P.240 掲載の参考文献
1) WHO Classification of Tumours Editorial Board (ed.) : WHO Classification of Tumors 5th ed. Digestive System Tumours. IARC, 2019.
 
2) Brierley JD, Gospodarowicz MK, Wittekind c (eds) : TNM Classification of Malignant Tumours 8th ed. Union for International Cancer Contro (l UICC), Wiley Blackwell, 2017
 
3) 日本肝胆膵外科学会 (編) : 臨床・病理 胆道癌取扱い規約 第6版. 金原出版, 2013
 
4) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版補訂版. 金原出版, 2019
 
5) 尾島英知, 坂元亨宇 : 肝臓. 外科病理マニュアル, 病理と臨床 26 (臨時増刊号) : 160-167, 2008
 
P.249 掲載の参考文献
1) Chuma M, Sakamoto M, Yamazaki K et al : Expression of profiling in multistage hepatocarcinogenesis : identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 37 : 198-207, 2003
PubMed
2) Shibata R, Mori T, Du W et al : Overexpression of cyclase-associated protein 2 in multistage hepatocarcinogenesis. Clin Cancer Res 12 : 5363-5368, 2006
PubMed
3) Ojima H, Masugi Y, Tsujikawa H et al : Early hepatocellular carcinoma with high-grade atypia in small vaguely nodular lesions. Cancer Sci 107 : 543-550, 2016
PubMed
4) Tsuchiya K, Komuta M, Yasui Y et al : Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. Oncology : 80 : 278-288, 2011
PubMed
5) Tsujikawa H, Masugi Y, Yamazaki K et al : Immunohistochemical molecular analysis indicates hepatocellular carcinoma subgroups that reflect tumor aggressiveness. Hum Pathol 50 : 24-33, 2016
PubMed
6) Durnez A, Verslype C, Nevens F et al : The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 49 : 138-151, 2006
 
7) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版補訂版. 金原出版, 2019, pp42-56
 
8) Rullier A, Le Bail B, Fawaz R et al : Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol 24 : 870-876, 2000
PubMed
9) Sasano H, Shizawa S, Suzuki T et al : Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy. Hum Pathol 26 : 1154-1156, 1995
PubMed
10) Zen Y, Harada K, Sasaki M et al : IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis ; do they belong to a spectrum of sclerosing pancreatitis? Am J Surg Pathol 28 : 1193-1203, 2004
PubMed
P.257 掲載の参考文献
1) Kondo F, Wada K, Nagato Y et al : Biopsy diagnosis of well-differentiated hepatocellular carcinoma based on new morphologic criteria. Hepatology 9 : 751-755, 1989
PubMed
2) Kondo F : Benign nodular hepatocellular lesions caused by abnormal hepatic circulation : etiological analysis and introduction of a new concept. J Gastroenterol Hepatol 16 : 1319-1328, 2001
PubMed
3) International Working Party : Terminology of nodular hepatocellular lesions. Hepatology 22 : 983-993, 1995 4) Bioulac SP, Balabaud C, Wanless I : Focal nodular hyperplasia and hepatocellular adenoma. in Bosman FT, Carneiro F, Hruban RH et al (eds), WHO Classification of Tumours of the Digestive System 4th ed. IARC, 2010, pp198-204
 
5) Bioulac SP, Kakar S, Nault JC : Hepatocellular adenoma. in WHO Classification of Tumors Editorial Board (ed.), WHO Classification of Tumors 5th ed. Digestive System Tumors. IARC, 2019, pp224-228
 
6) 近藤福雄, 近藤洋一郎, 江原正明他 : 微小および高分化型細胞癌の生検組織診断. 病理と臨床 11 : 943-951, 1993
 
7) Kutami R, Nakashima Y, Nakashima O et al : Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans. J Hepatol 33 : 282-289, 2000
 
8) Kondo F, Kondo Y, Nagato Y et al : Interstitial tumour cell invasion in small hepatocellular carcinoma. Evaluation in microscopic and low magnification views. J Gastroenterol Hepatol 9 : 604-612, 1994
PubMed
9) Sasaki M, Yoneda N, Sawai Y et al : Clinicopathological characteristics of serum amyloid A-positive hepatocellular neoplasms/nodules arising in alcoholic cirrhosis. Histopathology 66 : 836-845, 2015
PubMed
10) 近藤福雄, 副島友莉恵, 福里利夫 : 良性肝細胞性結節の病理診断 新WHO分類をふまえて. 肝臓 54 : 807-818, 2013
 
11) Nakashima O, Kurogi M, Yamaguchi R et al : Unique hypervascular nodules in alcoholic liver cirrhosis : identical to focal nodular hyperplasia-like nodules? J Hepatol 41 : 992-998, 2004
PubMed
12) Kondo F : Focal nodular hyperplasia-like lesions in heavy drinkers. Intern Med 48 : 1117-1123, 2009
PubMed
13) 近藤福雄 : 良性非腫瘍性肝細胞性過形成結節 (FNH類似病変). 病理と臨床 25 : 812-813, 2007
Medical*Online
14) Chuma M, Sakamoto M, Yamazaki K et al : Expression profiling in multistage hepatocarcinogenesis : identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 37 : 198-207, 2003
PubMed
15) Yamauchi N, Watanabe A, Hishinuma M et al : The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol 18 : 1591-1598, 2005
PubMed
16) Torbenson M, Zen Y, Yeh MM : AFIP Atlas of Tumor Pathology Series 4, Fascicle 27 Tumors of the Liver. American Registry of Pathology, 2018, pp55-67
 
17) 近藤福雄 : 肝細胞腺腫と限局性結節性過形成 : 新WHO分類をふまえた良性肝細胞性結節のあたらしい考え方. The Liver Cancer Journal 5 : 174-185, 2013
 
18) Kondo F, Koshima Y, Ebara M : Nodular lesions associated with abnormal liver circulation. Intervirology 47 : 277-287, 2004
PubMed

第4部 臨床との連携

P.271 掲載の参考文献
1) IARC Monographs Programme on the Evaluation of Carcinogenic Risks to Humans. http://monographs.iarc.fr/
PubMed
2) Yoshida H, Shiratori Y, Moriyama M et al : Interferon therapy reduces the risk for hepatocellular carcinoma : national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 : 174-181, 1999
 
3) Liaw YF, Sung JJ, Chow WC et al : Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351 : 1521-1531 2004
PubMed
4) Carrat F, Fontaine H, Dorival C et al : Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment : a prospective cohort study. Lancet 393 : 1453-1464, 2019
PubMed
5) Arase Y, Ikeda K, Murashima N et al : The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 79 : 1494-1500, 1997
 
6) Tarao K, Rino Y, Ohkawa S et al : Close association between high serum alanine aminotransferase levels and multicentric hepatocarcinogenesis in patients with hepatitis C virus-associated cirrhosis. Cancer 94 : 1787-1795, 2002
PubMed
7) Page JM, Harrison SA : NASH and HCC. Clin Liver Dis. 13 : 631-647. 2009
PubMed
8) Yamada R, Sato M, Kawabata M et al : Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology. 148 : 397-401, 1983
PubMed
9) Ebara M, Ohto M, Sugiura N et al : Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 5 : 616-626, 1990
PubMed
10) Rossi S, Fornari F, Buscarini L : Percutaneous ultrasound-guided radiofrequency electrocautery for the treatment of small hepatocellular carcinoma. J Intervent Radiology 8 : 97-103, 1993
 
11) 椎名秀一朗, 寺谷卓馬, 小尾俊太郎他 : Cool-tip型電極を用いた経皮的ラジオ波焼灼療法による肝細胞癌の治療. 肝臓 41 : 24-30, 2000
 
12) 大崎往夫, 木村達, 喜多竜一他 : 肝細胞癌に対する経皮ラジオ波熱凝固療法 (RFA) の検討. 肝臓 42 : 22-28, 2001
 
13) Seki T, Wakabayashi M, Nakagawa T : Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer 74 : 817-825, 1994
PubMed
14) Varela M, Real MI, Burrel M et al : Chemoembolization of hepatocellular carcinoma with drug eluting beads : efficacy and doxorubicin pharmacokinetics. J Hepatol. 46 : 474-481. 2007
PubMed
15) Llovet JM, Ricci S, Mazzaferro V et al : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 : 378-390. 2008
PubMed
16) Osaki Y, Nishikawa H : Treatment for hepatocellular carcinoma in Japan over the last three decades : Our experience and published work review. Hepatol Res 45 : 59-74, 2015
PubMed
17) Toyoda H, Kumada T, Osaki Y et al : Role of tumor markers in assessment of tumor progression and prediction of outcomes in patients with hepatocellular carcinoma. Hepatol Res 37 Suppl 2 : S166-171, 2007
 
18) Cucchetti A, Vivarelli M, Piscaglia F et al : Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol 43 : 310-316. 2005
PubMed
19) Izumi N. Hasegawa K, Nishioka Y et al : A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma. https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.4002
 
P.276 掲載の参考文献
1) Larsson SC, Wolk A : Overweight, obesity and risk of liver cancer : a meta-analysis of cohort studies. Br J Cancer 97 : 1005-1008, 2007
PubMed
2) Wang C, Wang X, Gong G et al : Increased risk of hepatocellular carcinoma in patients with diabetes mellitus : a systematic review and meta-analysis of cohort studies. Int J Cancer 130 : 1639-1648, 2012
PubMed
3) Tateishi R, Uchino K, Fujiwara N et al : A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan : 2011-2015 update. J Gastroenterol 54 : 367-376, 2019
PubMed
4) Younossi ZM, Koenig AB, Abdelatif D et al : Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 : 73-84, 2016
PubMed
5) Eguchi Y, Hyogo H, Ono M et al : Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan : a multicenter large retrospective study. J Gastroenterol 47 : 586-595, 2012
PubMed
6) 日本肝臓学会 (編) : NAFLD・NASH診療ガイド 2015. 文光堂, 2015
 
7) Williams CD, Stengel J, Asike MI et al : Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy : a pr ospective study. Gastroenterology 140 : 124-131, 2011
 
8) Kanwal F, Kramer JR, Mapakshi S et al : Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology 155 : 1828-37e2, 2018
PubMed
9) Tobari M, Hashimoto E : Characteristic features of nonalcoholic fatty liver disease in Japan with a focus on the roles of age, sex and body mass index. Gut Liver 2020, Jan 3. https://doi.org/10. 5009/gnl19236
 
10) Paradis V, Zalinski S, Chelbi E et al : Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis : a pathological analysis. Hepatology 49 : 851-859, 2009
PubMed
11) Anstee QM, Reeves HL, Kotsiliti E et al : From NASH to HCC : current concepts and future challenges. Nat Rev Gastroenterol Hepatol 16 : 411-428, 2019
PubMed
12) Torres DM, Harrison SA : Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma : fertile soil. Semin Liver Dis 32 : 30-38, 2012
PubMed
13) Yasui K, Hashimoto E, Komorizono Y et al : Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 9 : 428-433 ; quiz e50, 2011
 
14) Michelotti GA, Machado MV, Diehl AM : NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 10 : 656-665, 2013
PubMed
15) Yoshimoto S, Loo TM, Atarashi K et al : Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499 : 97-101, 2013
PubMed
16) Grohmann M, Wiede F, Dodd GT et al : Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC. Cell 175 : 1289-1306 e20, 2018
 
17) Salomao M, Remotti H, Vaughan R et al : The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis. Hum Pathol 43 : 737-746, 2012
PubMed
18) Salomao M, Yu WM, Brown RS Jr et al : Steatohepatitic hepatocellular carcinoma (SH-HCC) : a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 34 : 1630-1636, 2010
 
19) Shibahara J, Ando S, Sakamoto Y et al : Hepatocellular carcinoma with steatohepatitic features : a clinicopathological study of Japanese patients. Histopathology 64 : 951-962, 2014
PubMed
20) Golabi P, Fazel S, Otgonsuren M et al : Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore) 96 : e5904, 2017
PubMed
21) Younossi ZM, Otgonsuren M, Henry L et al : Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62 : 1723-1730, 2015
PubMed
22) Oliveira CP, Stefano JT, Carrilho FJ : Clinical patterns of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) : a multicenter prospective study. Hepatobiliary Surg Nutr 6 : 350-352, 2017
PubMed
23) Tokushige K, Hashimoto E, Yatsuji S et al : Prospective study of hepatocellular carcinoma in nonalcoholic steatohepatitis in comparison with hepatocellular carcinoma caused by chronic hepatitis C. J Gastroenterol 45 : 960-967, 2010
PubMed
24) Golabi P, Rhea L, Henry L et al : Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int 13 : 688-694, 2019
PubMed
25) Reig M, Gambato M, Man NK et al : Should patients with NAFLD/NASH be surveyed for HCC? Transplantation 103 : 39-44, 2019
 
P.287 掲載の参考文献
1) Matsui O, Kobayashi S, Sanada J et al : Hepatocelluar nodules in liver cirrhosis : hemodynamic evaluation (angiography-assisted CT) with special reference to multi-step hepatocarcinogenesis. Abdom Imaging 36 : 264-272, 2011
PubMed
2) Tsuboyama T, Onishi H, Kim T et al : Hepatocellular carcinoma : hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation. Radiology 255 : 824-833, 2010
PubMed
3) Kitao A, Zen Y, Matsui O et al : Hepatocellular carcinoma : signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features. Radiology 256 : 817-826, 2010
PubMed
4) Kitao A, Matsui O, Yoneda N et al : The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis : correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 21 : 2056-2066, 2011
PubMed
5) Imai Y, Murakami T, Yoshida S et al : Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma : correlation with histological grading. Hepatology 32 : 205-212, 2000
PubMed
6) Takehara Y, Ichijo K, Tooyama N et al : Breath-hold MR cholangiopancreatography with a long-echo-train fast spin-echo sequence and a surface coil in chronic pancreatitis. Radiology 192 : 73-78, 1994
 
7) Yoneda N, Matsui O, Kitao A et al : Benign hepatocellular nodules : hepatobiliary phase of gadoxetic acid-enhanced MR Imaging based on molecular background. Radiographics 36 : 2010-2027, 2016
PubMed
8) Kitagawa K, Matsui O, Kadoya M et al : Hepatocellular carcinomas with excessive copper accumulation : CT and MR findings. Radiology 180 : 623-628, 1991
 
9) Kitao A, Matsui O, Yoneda N et al : Hypervascular hepatocellular carcinoma : correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 265 : 780-789, 2012
PubMed
10) Yamashita T, Kitao A, Matsui O et al : Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology 60 : 1674-1685, 2014
PubMed
11) Kobayashi S, Matsui O, Gabata T et al : Hemodynamics of small sclerosing hepatocellular carcinoma without fibrous capsule : evaluation with single-level dynamic CT during hepatic arteriography. Abdom Imaging 33 : 425-427, 2008
PubMed
12) Sano K, Ichikawa T, Motosugi U et al : Imaging study of early hepatocellular carcinoma : usefulness of gadoxetic acid-enhanced MR imaging. Radiology 261 : 834-844, 2011
PubMed
13) Hayashi M, Matsui O, Ueda K et al : Correlation between the blood supply and grade of malignancy of hepatocellular nodules associated with liver cirrhosis : evaluation by CT during intraarterial injection of contrast medium. Am J Roentgenol 172 : 969-976, 1999
 
14) Kobayashi S, Matsui O, Gabata T et al : Gadolinium ethoxybenzyl diethylenetriamine pentaacetic Acid-enhanced magnetic resonance imaging findings of borderline lesions at high risk for progression to hypervascular classic hepatocellular carcinoma. J Comput Assist Tomogr 35 : 181-186, 2011
PubMed
15) Kobayashi S, Matsui O, Gabata T et al : Intranodular signal intensity analysis of hypovascular high-risk borderline lesions of HCC that illustrate multi-step hepatocarcinogenesis within the nodule on Gd-EOB-DTPA-enhanced MRI. Eur J Radiol 81 : 3839-3845, 2012
PubMed
16) Hamaoka M, Kozaka K, Matsui O et al : Early detection of intrahepatic cholangiocarcinoma. Jpn J Radiol 37 : 669-684, 2019
PubMed
P.299 掲載の参考文献
1) Morimoto M, Shirato K, Sugimori K et al : Contrast-enhanced harmonic gray-scale sonographic-histologic correlation of the therapeutic effects of transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Am J Roentgenol 181 : 65-69, 2003
 
2) Lencioni R, Cioni D, Crocetti L et al : Percutaneous ablation of hepatocellular carcinoma : state-of-the-art. Liver Transpl 10 (2 Suppl 1) : S91-97, 2004
 
3) Tanaka K, Okazaki H, Nakamura S et al : Hepatocellular carcinoma : treatment with a combination therapy of transcatheter arterial embolization and percutaneous ethanol injection. Radiology 179 : 713-717, 1991
PubMed
4) Morimoto M, Sugimori K, Shirato K et al : Treatment of hepatocellular carcinoma with radiofrequency ablation : radiologic-histologic correlation during follow-up periods. Hepatology 35 : 1467-1475, 2002
PubMed
5) Lim HL, Choi D, Lee WJ et al : Hepatocellular carcinoma treated with percutaneous radio-frequency ablation : evaluation with follow-up multiphase helical CT. Radiology 221 : 447-454, 2001
 
6) Sugimori K, Morimoto M, Shirato K et al : Radiofrequency ablation in a pig liver model : effect of transcatheter arterial embolization on coagulation diameter and histologic characteristics. Hepatol Res 24 : 164-173, 2002
 
7) Sugimori K, Nozawa A, Morimoto M et al : Extension of radiofrequency ablation of the liver by transcatheter arterial embolization with iodized oil and gelatin sponge : results in a pig model. J Vasc Interv Radiol 16 : 849-856, 2005
 
8) Fukuda H, Numata K, Hara K et al : Comparison of vascularity observed using contrast-enhanced 3D ultrasonography and pathological changes in patients with hepatocellular carcinoma after sorafenib treatment. J Cancer. 14 : 2408-2414, 2018
 
P.305 掲載の参考文献
1) 日本肝癌研究会 (編) : 臨床・病理 原発性肝癌取扱い規約 第6版補訂版. 金原出版, 2019
 
2) WHO Classification of Tomours Editorial Board (ed.) : WHO Classification of Tumours 5th ed. Digestive System Tumours. IARC, 2019
 
3) 日本肝臓学会 (編) : NASH・NAFLD の診療ガイド 2015. 文光堂, 2015
 

書評

最近チェックした商品履歴

Loading...